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ABSTRACT 
 In recent decades, drug-loaded carrier systems have become a viable option to 
replace or augment current, unsuccessful therapies that address a myriad of disease 
conditions.  In this area, a successful therapy needs to address the following parameters: 
specificity, long circulation, biocompatibility/biodegradability, desired pharmacokinetics 
of single & multiple therapeutics, carrier-cell interactions, and potential imaging 
capabilities. While various formulations have tackled some of these characteristics, a 
concrete methodology to design multifunctional particles addressing all parameters is 
currently lacking.  
 Herein, the method of electrohydrodynamic (EHD) co-jetting and downstream 
processing are used to design multifunctional particles with tunable characteristics that 
could be used to address all desired parameters. Specifically, each of the chapters address 
(i) the development of carriers with selective and orthogonal surface modifications using 
functional polymers incorporated into individual compartments for the addition of stealth, 
targeting, or therapeutic capabilities; (ii) the development of carriers with programmable 
physical properties such as shape, size, porosity, roughness, and charge that can 
determine the fate of a particle in the body, and the testing of nanoparticles in animal 
models to determine their biodistribution; (iii) the development of particles with complex 
degradation and release kinetics of therapeutics using rapidly degrading or stimuli-
responsive (pH, light, & oxidative stress) polymers; (iv) the design of multifunctional 
particles loaded with multiple therapeutics for cochlear delivery and their testing to 
determine the therapeutics’ release kinetics, the particles’ persistence & biodistribution in 
the cochlea, and the general biocompatibility of the system. Accordingly, this dissertation 
suggests the potential establishment of a toolbox that can be used for the design of 
particles with programmable properties for individual applications in the effective 
delivery of therapeutics.  
xix 
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CHAPTER 1 
Introduction 
 The material in this chapter has been adapted with minor modifications from the 
following articles: 
(1) S. Rahmani, J. Lahann, “Recent Progress with Multicompartmental 
Nanoparticles”, MRS Bull., 2014, 39 (03), 251-257.   
(2) S. Rahmani, T.-H. Park, A. F. Dishman, J. Lahann, “Multimodal Delivery of 
Irinotecan from Microparticles with Two Distinct Compartments”, J. Control. 
Release, 2013, 172, 239-245. 
 
 
1.1 Goals & Challenges of Drug Delivery 
  
 The advent of new technologies and the discovery of numerous life-saving 
therapeutics in the last several decades have drastically changed the field of medicine and 
have greatly increased the life expectancy and living conditions of patients suffering from 
a myriad of health related issues.1-3 While the medical and pharmaceutical fields have 
come a long way in diagnosing disease states and in finding therapeutics that can address 
them, the delivery of such therapeutics to the correct sites in the body and with the 
desired pharmacokinetics is not yet optimal.4, 5 This has posed significant hurdles in the
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treatment of patients, especially when the therapeutics are potent and any delivery to 
undesired sites in the body can lead to severe toxicities and low therapeutics indices.2, 6    
 Among the main challenges faced by current therapy methods, including the most 
common routes of oral consumption and injection of therapeutics, are their i) non-
targeted nature; ii) short circulation times; iii) requirement for repeated intake/injections 
to achieve appropriate pharmacokinetics; iv) their tendency towards cellular resistance; 
and v) observed severe toxicities which together lead to patient compliance issues and 
overall lower treatment outcomes.1 This is especially true in the case of cancer 
therapeutics (potent drugs designed for the destruction of cancerous tissue), where the 
side effects can be debilitating.7-10 On the other hand, biological therapeutics, such as 
growth factors and nucleic acids, have very short lifetimes within the body, and it is a 
challenge to achieve therapeutic efficacy with these molecules, especially since some 
have severe side-effects at higher doses.11-13  
 The use of drug delivery carriers can provide an alternative for the administration 
of therapeutics since particles have the potential to initially protect the encapsulated 
therapeutic, circulate in the blood stream, specifically deliver the therapeutic to the 
targeted site in the body, and release the drug in a manner that can ideally be adjusted to 
the pharmacokinetics of the selected therapeutic (Figure 1-1).14 In addition, such carriers 
can be biocompatible and/or biodegradable and intrinsically harmless to the body. These 
carriers can also contain contrast-imaging agents that can enable the tracking of such 
particles using various imaging systems (MRI, PET, CT, etc.), or, alternatively, be used 
for diagnostic applications.15, 16 Most contrast-imaging agents are potentially toxic and 
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are typically not targeted, and their incorporation into nanoparticles can result in the 
reduction of their toxic side effects and improve on their targeting capabilities. 
 First formulations of drug delivery carriers have been evaluated in clinical trials 
and some have already been turned into pharmaceutical products.17, 18 While these early 
formulations have demonstrated the clinical potential of prolonged release formulations, 
these carriers are still far from optimal and lack important aspects, such as active 
targeting, prolonged circulation, and tailored release kinetics.19 
 
 
1.2 Multifunctional Nanoparticle Formulations 
 
Nano- and micro-particles have demonstrated exceptional potential in a variety of 
areas, such as diagnostics and therapeutics.20 Recent improvements in particle fabrication 
methods, such as the expansion of compositional flexibility and physical as well as 
Figure 1-1: The capabilities of a multifunctional carrier. Multifunctional particles should be able to 
encapsulate and protect therapeutics; circulate in the blood stream and avoid uptake and clearance; 
specifically deliver and release the therapeutic to the targeted site in the body; and provide imaging 
capabilities for potential tracking of the nanoparticles and for diagnostic applications.    
	   4 
chemical tunability, have resulted in increased functional versatility of colloidal particles. 
In particular, precise engineering of shape, size, surface structures, and mechanical 
properties has been accomplished by several processes.21-23 Beyond the current state of 
the art, the complementary control of internal (bulk) and external (surface) features has 
emerged as an important design parameter for multifunctional particles, where the bulk 
and surface of each particle is no longer isotropic in its functionality and characteristic. 
These anisotropic particles may feature two or more distinct compartments, controlled 
interfacial patterns, or compositionally distinct materials domains in a single particulate 
entity.24-34 Novel self-assembled particles, such as the multifunctional particles, may find 
diverse applications in multiplexed bioassays,35 vehicles for multiple therapeutic 
modalities,36 biohybrid materials,37 or microactuators.38, 39 
Compositional bulk anisotropy may enable unique particle properties. Here, a 
particle configuration that features materials compartmentalized within a monolithic 
particle can impart entirely new properties and may be a decisive functional parameter, 
being similarly as important as the actual chemical makeup.23 On the other hand, 
anisotropic surface functionalization can be realized in the form of patchy particles, 
where different surface patches are associated with different chemically or functionally 
orthogonal surface properties. Particles with this type of surface anisotropy can exhibit 
bipolar characteristics, such as particles that are simultaneously hydrophilic and 
hydrophobic, or can be used for self-assembly and drug delivery.40-42 Independent control 
of the composition of individual compartments of the same particle allows for inclusion 
of materials with highly dissimilar sets of properties. This approach forms the foundation 
for the controlled release of multiple drugs with independent release kinetics (provided 
	   5 
that each drug is loaded in a separate compartment) or a combination of fully decoupled 
modalities for combined imaging and therapy (theranostics).43 Current carrier systems 
that are loaded with multiple therapeutics in a single isotropic particle lack this 
characteristic and may even promote antagonistic cross-interactions between drugs.19, 44-46  
Compartmentalized particles can be fabricated by a range of different methods. In 
particular, the self-assembly of block copolymers47, 48 or the use of intended phase 
separation during seeded polymerizations (where two non-miscible solvents are used to 
create an emulsion, at the interface of which two different polymer brushes are grown on 
the same nucleation seed), are widely pursued approaches toward anisotropic 
nanoparticles.49, 50 More recently, lithographic and template-assisted methods have 
attracted wider attention for their great flexibility in constructing non-spherical Janus 
particles, such as disks, rods, cubes, etc.51-53 Recently, droplet-based strategies have 
found use for the preparation of multifunctional particles. In some instances, microfluidic 
techniques were combined with photolithographic methods to prepare particles with 
uniform size and shape. In some examples, this approach resulted in particles with 
impressive complexity of inner and outer geometries.54-56 However, a narrow choice of 
materials is available for these rather specialized approached, and relatively large particle 
sizes are prepared. Further progress is needed to ensure diversification of materials 
choices and to augment the establishment of widely applicable processing methods.  
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1.3 Electrohydrodynamic Co-Jetting 
  
Arguably, one of the most versatile approaches toward anisotropic particles, 
cylinders, fibers, and fiber scaffolds is based on electrohydrodynamic (EHD) co-jetting; a 
technology pioneered in the Lahann Lab at the University of Michigan.23 This technology 
has been used for the fabrication of organic and inorganic nanoparticles.57, 58 This 
research has been inspired by work done by Loscertales, et al., where coaxial, electrified 
liquid jets were used to fabricate nano- and micro-droplets with a core-shell structure, and 
built upon pioneering work done by Gupta, et al., where side-by-side electrospinning was 
used to create multifunctional, but not multicompartmental, nanofibrous meshes.59-63 
Electrospraying and electrospining processes have been applied to polymer 
solutions to establish straightforward methods for the preparation of nano-/microparticles 
using high electrical voltages as driving forces for the transport of polymer solutions. 
Importantly, the precise control of critical polymer solution properties such as material 
selection, concentration, viscosity, and conductivity can result in a diverse range of sizes 
and shapes in the nanometer and micron range.64 Building on these well-established 
methods, EHD co-jetting now involves the use of two or more flows that are run through 
parallel capillary nee61dles in a side-by-side configuration. Thus, there is no convective 
mixing, and a very stable interface can be established between the two jetting solutions. 
Application of an electric field to the compound droplet, which forms at the outlet of the 
two capillary needles, results in distortion of the droplet into a stable cone and subsequent 
formation of an electrified polymer jet. The rapid acceleration of the viscoelastic jet with 
velocities on the order of 250 m/s, comparable to a rocket launch, can lead to a reduction 
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in jet diameter by several orders of magnitude and a simultaneous increase in surface area. 
This induces instantaneous evaporation of the solvents and results in solidification of the 
non-volatile components. Because solidification is extremely fast, surface energy driven 
reorientation of the polymers into a thermodynamically more stable core–shell 
configuration is restricted, and the initial flow-determined configuration can be 
maintained. Thus EHD co-jetting uses relatively simple manipulation of liquid 
geometries followed by rapid solidification to provide access to solid nano- and 
microfibers with architectures that would be otherwise impossible, or at least extremely 
difficult, to achieve. As a result, the particles are trapped in the initial, flow-determined 
compartmentalized geometry, rather than taking on the energetically most favorable 
constellation, which is in almost all cases a core–shell particle. Not surprisingly, however, 
the preparation of bicompartmental polymer particles via EHD co-jetting requires 
delicate control of several competing factors. 
 Initial work with EHD co-jetting has been focused on water-soluble polymers 
because water-based jetting systems typically exhibit lower toxicity, which is a critical 
factor for biomedical applications.59 The preparation of bicompartmental particles using 
the EHD co-jetting approach was first demonstrated with aqueous solutions of 
polyacrylic acid (PAA) or poly(ethylene glycol) (PEG).65 The relatively high free surface 
energy of water results in the formation of a nearly spherical droplet, where the biphasic 
flow interface is maintained, and a stable cone is formed (Figure 1-2). The 
compartmentalization is due to the particular manipulation of the liquid phases. However, 
the use of water-soluble polymers for the fabrication of particles also requires post-
fabrication modification to ensure stability under physiological conditions. In the case of 
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the above-mentioned poly(acrylamide-co-acrylic acid) (P(AAm-co-PAA)) particles, 
thermal imidization of carboxylic acid and amide groups provided sufficient particle 
stability and resulted in controllable swelling in water.66 
More recently, EHD co-jetting of organic-soluble polymers has been 
demonstrated to yield anisotropic micro- and nano-particles. In particular, the EHD co-
jetting of organic solution of poly(lactic-co-glycolic acid) (PLGA) has resulted in 
Figure 1-2: (A) Schematic description of the electrohydrodynamic (EHD) co-jetting process, which can 
lead to either particles (electrospraying) or fibers (electrospinning). (B) A photograph of a typical 
Taylor cone and jet ejection during EHD co-jetting. The interface between the two aligned polymer 
solutions is clearly observed. (C) Examples of particles and fibers obtained from the EHD co-jetting. 
Particles were composed of poly(lactic- co-glycolic acid) polymers, and a different dye was 
incorporated into each compartment to display their anisotropic nature. Imaging was done with a 
confocal laser scanning microscope.31 
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bicompartmental particles and fibers.67 Because of their biodegradability, these particles 
may constitute promising building blocks for drug delivery and tissue engineering.68 
Systematic analysis of the EHD co-jetting system reveals that both solution and 
process parameters have to be controlled to achieve a particular compartmentalization, 
shape, and size.68, 69 In addition, EHD co-jetting can be affected by a number of 
environmental factors, such as temperature, pressure, and humidity. Subtle alteration of 
these variables may lead to significant variation in particle size, shape, surface, 
morphology, and porosity. A wide range of PLGA particle characteristics has been 
achieved through variation of polymer concentration and flow rate of PLGA fluids as 
control parameters.68 The viscosity of a polymer solution, a direct consequence of 
polymer concentration and molecular weight, significantly influences jet atomization and 
evaporation rates as well. For example, fiber architectures are preferentially prepared at 
higher concentrations and low flow rates, because more viscous solutions can resist the 
breakup of the jet.  
Because the capillary needle configuration primarily determines the compartment 
geometry of particles and fibers fabricated by the EHD co-jetting process, an increase in 
the number of capillaries can provide access to particles with more than two 
compartments.69, 70 The EHD co-jetting of aqueous P(AAm-co-PAA) solutions with a 
three-needle setup resulted in tricompartmental particles with diameters between 
hundreds of nanometers and a few micrometers.69 On the other hand, multicompartmental 
fibers with as many as seven distinct compartments can be prepared by the EHD co-
jetting of PLGA solution (Figure 1-3).70 Combined with low flow rates and high solvent 
volatility, highly viscous PLGA solutions contribute to the formation of a very stable and 
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continuous jet, which results in fibers with multiple compartments only minimally 
affected by the perturbations during EHD co-jetting, such as humidity, air flow, charge 
build-up, and temperature fluctuations.70 Moreover, the flow arrangement as well as the 
nozzle geometry can influence the orientation of compartments. For example, three 
parallel-aligned needles in a side-by-side configuration yield sandwiched compartments, 
which can show all possible “isomers” of tricompartmental fibers (Figure 1-3 a-c). On the 
other hand, a concentric side-by-side three-needle configuration realizes three pie-shaped 
Figure 1-3: Confocal laser scanning microscope images of the cross-sectional view of 
multicompartmental microfiber bundles with two to seven compartments. The colored circles in the 
small inset boxes represent the number of compartments, their orientation, and the dyes used in each. In 
(A–C), tricompartmental microfibers with a side-by-side geometry are shown where the dye in each 
compartment has been switched to display the versatility of the fabrication method. In (B), the 
individual compartments in one fiber have been outlined, where “C” represents “Compartment.” (D) 
Tricompartmental microfibers with a pie-shaped structure. (E–G) Tetra-compartmental microfibers, 
where the internal geometry of the fibers (side-by-side in (e) and pie-shaped in (f–g)) and their 
compartment size ((F) versus (G)) are compared. (H–I) Seven-compartmental microfibers and their 
respective compartment size. The scale bars represent 20 mm for all figures.75  
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compartments (Figure 1-3 d). When the jetting solutions were arranged in an alternating 
sequence, scaffolds consisting of striped microfibers with four distinguishable 
compartments in series were prepared (Figure 1-3 e). Similarly, more complicated 
rosettes consisting of seven compartments were prepared (Figure 1-3 h-i). Importantly, 
these multicompartmental microfibers can be used as platforms to transfer the well-
defined anisotropic structures to cylindrical colloids by microsectioning.71 
Differential reactivity of individual compartments within a compositionally 
anisotropic particle provides access to interesting particle architectures that would be 
otherwise impossible, or at least extremely difficult, to achieve. PLGA microdisks were 
prepared, which were composed of a quarter compartment containing a mixture of 
poly(N-isopropyl acrylamide) (PNIPAM) and PLGA. Selective removal of the PNIPAM 
compartment by exposure to water led to “Pac-Man”-like particles (Figure 1-4).71 
Spatially controlled photo-cross-linking reactions of poly(vinyl cinnamate) (PVCi) 
containing compartments of bicompartmental PLGA microparticles led to novel types of 
particles with respect to degradation rates, solvent resistance, and mechanical properties.3 
In addition to being used in biomedical applications such as selective release of 
therapeutics, such particles can be used for on-demand self-assembly of anisotropic 
particles. Treatment with chloroform yielded semicapsules manifesting small pores on 
their surface (Figure 1-4).3 Such pores can be used to accelerate the selective degradation, 
or the release of therapeutics, from one compartment. 
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Anisotropic surface modification is one of the simplest methods to prepare Janus 
particles with different surface patches. The surface properties of these particles can be 
controlled effectively. Therefore, the selective surface functionalization of 
compartmentalized particles may offer novel properties, because distinctive functions can 
be given to external as well as internal design aspects in an independently controllable 
manner. Adding functionalized polymers into different jetting solutions used in the EHD 
co-jetting process allows for selective modification of certain parts of the particle. 
Ultimately, it may even be possible to simultaneously present multiple chemical moieties 
on parts of the particle surface. In one specific case, the EHD co-jetting of P(AAm-co-
Figure 1-4: (A) A confocal laser scanning microscope image of bicompartmental poly(lacticco-glycolic 
acid) (PLGA) microdisks prepared by electrohydrodynamic co-jetting and subsequent microsectioning. 
The smaller one-quarter compartment (green) comprises a water-soluble polymer (PNIPAM, left), 
which was selectively removed to yield “Pac-Man”-like particles (right, scale bar: 10.0 µm for both the 
fluorescent and differential interference contrast images). (B) Porous hemicapsules obtained from 
spatially controlled photo-cross-linking and subsequent solvent treatment of bicompartmental PLGA 
particles containing poly(vinyl cinnamate) (PVCi) in one compartment. Note: h, Planck’s constant; ν, 
frequency; PNIPAM, poly( N-isopropyl acrylamide).3,76  
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AA) solutions was used to incorporate biotin- and acetylene-modified P(AAm-co-AA) in 
bicompartmental particles. In addition, surface modification of the entire surface area 
with PEG was necessary to minimize non-specific binding. Selectively functionalized 
particles had significantly higher binding as compared to PEG-containing particles.37 
In another case, selectively acetylene-functionalized bicompartmental particles 
were prepared from the EHD co-jetting of PLGA solutions, where one of the solutions 
further contained poly[lactide-co-propagylglycolide]. Importantly, the addition of the 
acetylene-modified PLGA did not disturb the co-jetting process.66 The mapping of the 
vibrational signature via confocal Raman spectromicroscopy confirmed the anisotropic 
distribution of the acetylene groups. The latter are characterized by a strong Raman band 
at 2100–2020 cm–1.72 Finally, the click reaction with azide-PEG-amine confirmed the 
selective modification of one hemisphere. Similarly, spatioselectively modified PLGA 
particles showed directional self-assembly of bicompartmental particles onto substrates.72  
In a straightforward extension of the microfiber work, we were able to create 
microcylinders with multicompartmental architectures through a semi-automated 
microsectioning process.71 The critical engineering advance was the preparation of 
perfectly aligned fiber scaffolds. This was achieved by jetting the microfibers on a 
spinning wheel where the spinning frequency was matched to the jetting velocity. Figure 
1-5 shows examples of different types of microcylinders that were prepared following 
this procedure. Variation of the microscectioning amplitude results in 
multicompartmental microcylinders with different aspect ratios. The improved 
understanding of the influence of different jetting parameters has allowed for varying the 
diameter of the microcylinders/microfibers from tens of microns to hundreds of 
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nanometers. The fact that multiple, distinct compartments can be realized within the same 
microcylinder can give rise to asymmetric properties within the same microcylinder. For 
instance, two (or more) compartments may have very distinct mechanical properties. In 
this case, the multicompartmental architecture will be profoundly distinct from a simple 
blending of the individual polymers.73 
Figure 1-5: Fabrication of bicompartmental fibers and microcylinders based on electrohydrodynamic 
co-jetting. In (A–D), the fabrication of microcylinders from microfibers is shown: (A) the 
electrospinning method, types of needles used, and the collecting wheel used for microfiber fabrication; 
(B–C) the cryosectioning procedure used to process the microfibers into uniformly sized 
microcylinders; and (D) a scanning electron microscope image of uniformly sized microcylinders 
fabricated through this process (scale bar is 100 mm). In (E), the top square in each column represents 
the overlay confocal laser scanning microscope (CLSM) image of the particles, while each subsequent 
lower square displays the individual CLSM channels representing a single compartment. Scale bars are 
10 µm unless otherwise noted; the scale bar in the bottom row of each column is the same for the entire 
column. (F) Bicompartmental microcylinders composed of a hydrogel/organogel that can undergo 
reversible, autonomous switching. Microcylinders are about 20 microns in size for imaging reasons but 
can be prepared with submicron diameters. 75,78 
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While electrospraying and electrospinning can utilize a wide range of polymers, 
electrohydrodynamic (EHD) co-jetting has so far been accomplished with a limited set of 
polymers that have similar solution properties. The formation of a stable cone during 
EHD co-jetting is typically easier to achieve when key solution parameters of the jetting 
solutions, such as conductivity, viscosity, and density are similar for the different jetting 
flows. Beyond the expansion of the EHD co-jetting process to increasingly different sets 
of polymers, such as water−organic swelling polymers and thermoresponsive/ 
photoresponsive polymers, further modification of the jetting process, including the use 
of novel needle configurations, different combinations of solvents, and sacrificial 
templating, may allow for exotic types of multifunctional compartmental particles with 
dissimilar properties. 
Nanometer- and micron-scale control of biodegradable materials is essential for 
many biomedical applications, including controlled drug delivery, regenerative medicine, 
or simultaneous imaging and diagnosis applications. The anisotropic surface 
functionalization of multicompartmental poly (lactic-co-glycolic) acid particles has the 
potential to satisfy such important criteria. 
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1.4 Objectives of This Work 
 
 The major objectives of this dissertation have focused on the development of a 
toolbox for the fabrication of multifunctional carriers, capable of programming desired 
properties for a given application. The engineering of multifunctional microparticles for 
cochlear delivery using this toolbox is demonstrated. Specifically, the following aims 
were established (Figure 1-6). 
 
Aim 1: To develop carriers with selective & orthogonal surface modifications. Here, we 
have focused on the synthesis and selective incorporation of functional polymers in 
individual compartments and their use for the creation of orthogonal patches on the 
particles. Such patches can be used for the incorporation of stealth, targeting, or 
therapeutic capabilities. 
 
Aim 2: To develop carriers with programmable physical properties. Given the 
importance of a particle’s physical characteristics in determining its fate in the body, here 
the control over these properties were explored. Particles with various properties such as 
different shapes, sizes, porosities, textures, and charges were fabricated and 
characterized. Additionally, nanoparticles were synthesized in high yields and their 
separation into uniform fractions using centrifugation was demonstrated. Nanoparticles 
were also tested in animal models to determine their biodistribution and circulation times.  
 
	   17 
Aim 3: To develop particles with complex release kinetics of therapeutics. A major 
factor in determining the success of a drug-loaded particle is dependent on the precise 
control over the release kinetics of therapeutics incorporated within it. Here we 
demonstrated the controlled and stimuli responsive degradation and release of 
therapeutics from particles by changing the functional polymers used in their bulk.  
 
Aim 4: To design particles for delivery of therapeutics to the cochlea. The prolonged 
release of multiple factors within the cochlea can potentially result in the survival of hair 
cells and thereby enhance the level of hearing for individuals suffering from severe 
hearing loss. Here, we have demonstrated the design of particles loaded with piribedil 
(small molecule therapeutic) and GDNF (Glial Derived Neurotrophic Factor), and their 
respective release from the particles for future use in this application. The survival and 
distribution of the particles over a seven-day period and the general biocompatibility of 
the particles in the cochlea is also demonstrated.  
Figure 1-6: Schematic illustration of the aims addressed in this dissertation. (A) Distinct surface 
patches on the particles. (B) Programmable physical properties. (C) Complex release kinetics. (D) 
Design of multifunctional particles for cochlear delivery. 
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CHAPTER 2 
Fabrication of Chemically Orthogonal Multi-Patch Particles 
 The material in this chapter has been adapted with minor modifications from the 
following articles: 
(1) S. Rahmani, S. Saha*, H. Durmaz*, A. Donini, A. C Misra, J. Yoon, J. Lahann, 
“Chemically Orthogonal Three-Patch Microparticles”, Angew. Chem. Int. Ed., 
2014, 53, 2332-2338.   
(2) S. Rahmani, S. Hwang, S. Saha, H. Durmaz, P. S. Lown, J. Lahann, “Self 
Assembly of Multicompartmental Disks Using Selective Surface Modifications”, 
In preparation. 
 
 
2.1 Motivation and Background 
 
 The directionally controlled presentation of chemical ligands on the surface of 
particles defines critical materials processes, such as three-dimensional gelation,74, 75 
directed self-assembly,24, 76-81 or the controlled interaction of particles with biological 
cells.82, 83 While the spatially controlled presentation of chemical and biological ligands is 
well established for two-dimensional substrates,84-89 very few methodologies exist for the 
spatially controlled decoration of three-dimensional objects, such as microparticles.80, 90-94 
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Many of the patterning methods for two-dimensional substrates including 
photolithography, microcontact printing, dip-pen nanolithography or block copolymer 
micelle nanolithography,87, 95-97 are not easily extendable to the three-dimensional 
surfaces of microparticles. Thus, there is a clear need for efficient microstructuring 
methodologies for meso-scale particles and some of the more promising strategies 
include microfluidic and microforming techniques,92, 98-102 template-assisted 
polymerizations,103-108 electrohydrodynamic co-jetting,37, 64-67, 72, 109, 110  or the use of 
pickering emulsions.111-113 With the requirement for spatially controlled immobilization 
of ligands also comes an increased need for the parallel immobilization of multiple, 
chemically distinct ligand on defined and independent interfacial patches of the same 
object. While most multi-ligand strategies have relied on statistical attachment of ligand 
mixtures,114-119 several studies have emphasized the need for the independent attachment 
of two or more ligands on the same surface via orthogonal immobilization strategies.120-
122 In this case, an important prerequisite is the compatibility with the biological 
“reaction” environment. Bertozzi et al. coined the term bio-orthogonal ligation to express 
the need for chemical selectivity relative to (i) the biological environment and (ii) the 
different types of ligands to be co-presented on different surface patches.123-125 Typically, 
different orthogonal immobilization schemes take advantage of click-type reactions and, 
in case of two-dimensional substrates, have been well-established,126 including “double-
click” strategies.127, 128 Recent work has revealed the potential of particles with multiple 
surface patches, however, the orthogonal functionalization of different surface locations 
poses significant challenges.129-134 In this chapter, we now report the spatially controlled 
immobilization of three chemically distinct patches on the same microparticle via 
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orthogonal surface reactions. Combining electrohydrodynamic co-jetting with synthetic 
polymer chemistry, we were able to create two- and three-patch microparticles displaying 
chemically orthogonal anchor groups on three distinct surface patches of the same 
particle. Using this technique, the attachment of stealth and targeting ligands on separate 
patches of particles and potential applications in self-assembly of unique structures were 
explored.  
 
 
2.2 Experimental Methods 
 
2.2.1 Materials 
 
 O-benzyl-L-serine was purchased from Alfa Aesar and diethyl ether was 
purchased from Acros Organics. Triethyl amine, bromoacetyl bromide, dimethyl amino 
pyridine, benzyl alcohol, l-lactide, tin (II) ethyl hexanoate, anhydrous toluene, palladium 
10% wt. on activated carbon, anhydrous tetrahydrofuran (THF), 4-methylbenzophenone, 
carbon tetrachloride, N-Bromosuccinimide, benzoyl peroxide, sodium cyanide, 
hydrochloric acid, tetraethylammonium chloride, palladium acetate, diphenylphosphine, 
1-methyl-2-aminoterephthalate, potassium iodide sodium sulfite, sodium sulfate, sodium 
chloride, sodium methoxide, dimethylsulfoxide, ethyl acetate, magnesium sulfate, silver 
perchlorate, methyl glycolate, potassium tert butoxide, bromoform, hexane, 
cycloheptene, poly(lactide-co-glycolide) (PLGA) 85:15, azide-PEGm, azide-PEG-azide, 
chloroform, dimethylformamide (DMF), MEHPV (polymeric dye), methanol, Tween 20, 
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phosphate buffered saline (PBS), and N-(3-Dimethylaminopropyl)-N’-ehtylcarbodiimide 
hydrochloride (EDC) were purchased from Sigma-Aldrich, USA. Sulfuric acid, 
acetonitrile, sodium nitrite, dichloromethane, sodium carbonate, acetone, Optimal Cutting 
Temperature (OCT) compound, and N-(hydroxysulfosuccinimide) (Sulfo-NHS) were 
purchased from Fisher Scientific, USA. Hydrogen was provided by Cryogenic Gases. 
Carboxyl-PEG-Folic acid molecular weight 5 kDa, amine-PEG-FITC molecular weight 5 
kDa, azide-PEG-FITC molecular weight 3.4 kDa, amine-PEG-Rhodamine molecular 
weight 3.4 kDa, and carboxyl-PEG-rhodamine molecular weight 3.4 kDa were purchased 
from Nanocs, USA. Albumin from Bovine Serum (BSA), Tetramethylrhodamine 
conjugate, TRITC-StreptavidinTM, and Alexa Fluor ® 647 StreptavidinTM were purchased 
from Life Technologies-Invitrogen, USA. Amine-dPEG23-biotin molecular weight 1.3 
kDa and azide-dPEG47-biotin molecular weight 2.4 kDa were purchased from Quanta 
Biodesign, Ltd., USA. Thiol-iRGD-FITC was generously provided by the Professor 
Ruoslahti’s laboratory at Sanford-Burnham Medical Research Institute.  
 
 
2.2.2 Synthesis & Characterization of Functional Poly (Lactide -co-Glycolides) 
  
 The synthesis and full characterization of functional polymers used in this chapter 
were graciously done by Dr. Sampa Saha and Dr. Hakan Durmaz and are included in 
Appendix A. 
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2.2.3 Fabrication of Microparticles & Their Characterization 
 
 Microparticles were fabricated as described previously by Bhaskar, et al.71 The 
jetting solutions were composed of PLGA 85:15 at 30% w/v in a 97:03 ratio of 
chloroform to DMF. For microparticles containing polymers 1-5, the functional polymers 
were added as an additive at 25% weight of the PLGA 85:15, with an exception to the 
polymer 5 used for the bicompartmental microparticles. In this case, the polymer 5 used 
had a molecular weight of approximately 70 kDa and was used as 25% w/w of the PLGA 
85:15 and not as an additive. To fabricate the fibers, the polymer solutions were flown 
through syringes tipped with 26 gauge metal needles at 0.03-0.05 ml/hr. The EHD 
conditions were a distance of 5-10 cm, RT, and a voltage of 10-12 kV. A rotating 
cylinder wrapped with aluminum foil and coated with OCT was used as the collector. 
Once jetted, the collector was placed in vacuumed to dry the fibers and then embedded in 
a mold filled with OCT for cryosectioning.73 A HISTO-550 Cryostat at the Microscopy & 
Imaging Laboratory facilities at the University of Michigan was used to section the 
embedded fibers at 5 µm. Once sectioned, the microparticles were washed several times 
with deionized (DI) water and 1% Tween 20 to remove the excess OCT. The 
microparticles were filtered with 40 and 10 µm filters to remove larger aggregates before 
use. The microparticle’s characterizations were done with CLSM (Confocal Laser 
Scanning Microscopy) using an Olympus Confocal Microscope and an Amray SEM 
(Scanning Electron Microscopy) at Microscopy & Imaging Laboratory facilities at the 
University of Michigan. For Raman-Confocal imaging, the microparticles were 
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lyophilized to remove excess water, deposited on glass slides, and characterized via the 
Raman-Confocal microscope using a 532 nm laser and an integration time of 0.5 seconds.    
  
 
2.2.4 Creation of Orthogonal Patches on Particles  
 
 For EDC/Sulfo-NHS chemistry with polymer 1, microparticles were incubated 
with 0.33 mg of EDC in 0.33 ml of buffer for 10 min, followed with 10 minutes 
incubation with 0.03 mg of sulfo-NHS in 0.33 ml of buffer to activate the carboxyl 
groups.  Once activated, 1 mg of amine-PEG-Rhodamine, 0.22 mg of amine-PEG-biotin, 
or 1 mg of amine-PEG-FITC in 0.33 ml of buffer were added to the solution and 
incubated for 2 hours.  The microparticles were then washed numerous times to remove 
unreacted material.  Microparticles reacted with amine-PEG-biotin were further 
incubated with 100 µg of Alexa Fluor ® 647 StreptavidinTM in 1 ml of buffer for 3 hours 
to label the biotin before being washed and imaged with CLSM.  The buffer used was 
PBS with 1% v/v Tween 20 and all reactions were done at RT on a rotator. 
 For EDC/Sulfo-NHS chemistry with polymer 2, 0.33 mg of EDC in 0.33 ml of 
buffer was added to 1-1.5 mg of carboxyl-PEG-Rhodamine or carboxyl-PEG-folic acid 
for 10 min, followed with 10 minutes incubation with 0.033 mg of sulfo-NHS in 0.33 ml 
of buffer to activate the carboxyl groups.  Once activated, the microparticles containing 
polymer 2 in 0.33 ml of buffer were added to the mixture and incubated for 2-3 hours. 
The microparticles were washed numerous times before imaging with CLSM.  For the 
particles labeled with folic acid, they were incubated in primary and secondary antibodies 
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for 3 hours each, respectively. The particles were washed in between each step and 
numerous times after the final step before imaging with CLSM. The buffer used was PBS 
with 1% v/v Tween 20 and all reactions were done at RT on a rotator.  
 For Staudinger ligation with polymer 3, microparticles were incubated overnight 
with 20 mg of azide-PEG-biotin in 1 ml of buffer.  The microparticles were then washed 
numerous times to remove unreacted material.  Once washed, the microparticles were 
incubated with 100 µg of TRITC-StreptavidinTM to label the biotin before washing again 
to remove unreacted material and imaging with CLSM.  The buffer used was DI water 
with 1% v/v Tween 20 and all reactions were done at RT on a rotator. 
 For photoreactive chemistry with polymer 4, the microparticles were incubated 
with 0.4-1 mg of BSA-tetramethylrhodamine conjugate in 1 ml of buffer for 1.5-2.5 
hours before UV’ing at 365 nm for 30 minutes with a handheld UV lamp from Ultra 
Violet Products, Ltd.  The microparticles were then washed to remove unreacted material 
before imaging via CLSM.  The buffer used was PBS with 1% v/v Tween 20 and all 
reactions were done at RT.   
 For copper free click chemistry with polymer 5, microparticles were incubated 
overnight with 20 mg of azide-PEG-biotin or 10 mg of azide-PEG-FITC in 1 ml of 
buffer.  The microparticles were then washed numerous times to remove unreacted 
material. Microparticles reacted with azide-PEG-biotin were incubated with 100 µg of 
Alexa Fluor ® 647 StreptavidinTM to label the biotin.  The microparticles were washed 
again to remove unreacted material before imaging with CLSM.  The buffer used was DI 
water with 1% v/v Tween 20 and all reactions were done at RT on a rotator.  
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 For copper click chemistry with polymer 6 or 7, disks were incubated overnight 
with 1.33 mg of copper sulfate pentahydrate, 5.33 ascorbic acid, and 20 mg of azide-
PEG-biotin or 10 mg of azide-PEG-FITC in 1 ml of buffer.  For complete PEG-ylation of 
disks (needed for drug delivery), 90-180 mg of azide-PEGm (5 kDa) was used, while for 
the self-assembly particles 10 mg of azide-PEG-azide was used to covalently link the 
disks together. The disks were then washed numerous times to remove unreacted 
material. If unreacted copper was present, the disks were incubated with a 10 mM EDTA 
solution (+0.01% v/v Tween) for 2-4 hours prior to the washes.  Disks reacted with azide-
PEG-biotin were incubated with 100 µg of Streptavidin-Alexa 647 or 40-100 µg 
Streptavidin-TRITC to label the biotin.  The disks were washed again to remove 
unreacted material before imaging with CLSM.  The buffer used was DI water with 1% 
v/v Tween 20 and all reactions were done at room temperature on a rotator.  
 For thiol-ene reaction with polymer 7, disks were incubated overnight with 10 mg 
of thiol-PEG-FITC or 1 mM of thiol-iRGD-FITC in 1 ml of buffer.  The disks were then 
washed numerous times to remove unreacted material.  The buffer used was bicarbonate 
buffer (pH 10) with 1% v/v Tween 20 and all reactions were done at room temperature on 
a rotator.  
 
 
2.2.6 Fabrication of Microparticles Responsive to an External Magnetic Field 
 
 To create anisotropic microparticles that respond to an external magnetic field, 
particles incorporating iron oxide in one compartment were fabricated. Similar to the 
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fabrication of the above-mentioned disks, fibers composed of PLGA and polymer 5 in 
one compartment were fabricated where the compartment containing polymer 5 also 
contained 3% w/w iron oxide nanoparticles. The resulting uniform fibers were micro-
sectioned at 5 µm, washed, and purified in the same manner. The assembly of the 
microdisks using an external magnetic field was graciously done by Dr. Sangyeul 
Hwang. 
 
 
2.3 Results and Discussion 
 
Fabrication and Analysis of Chemically Orthogonal Three-Patch Microparticles: 
 As depicted in Figure 2-1, the preparation of multi-patch microparticles was 
achieved by electrohydrodynamic (EHD) co-jetting of up to three parallel polymer 
solutions. The EHD co-jetting process yielded well-defined microfibers that were 
subsequently sectioned into well-defined multi-patch particles.71 In this study, we 
employed disk-shaped microparticles with an average diameter of 10-15 µm and an 
average aspect ratio of 1:2 (height:diameter). Size and shape of the microparticles can be 
controlled within a broad range,71 but were ultimately selected in this work to be in the 
10-20 µm range for practical reasons, such as optimal imaging of the individual chemical 
surface reactions via fluorescence and Raman confocal microspectroscopy. The base 
polymer used throughout this study was a biodegradable poly(lactide-co-glycolide) 
(PLGA) polymer. To impart chemical orthogonality, several different chemically 
functionalized polylactide (PLA) polymers were synthesized. The chemically orthogonal 
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PLA derivatives can be added to the different PLGA compartments in order to provide 
chemical patches for directionally controlled surface modification. Here, a set of eight 
different PLA derivatives was selected for their ability to support orthogonal surface 
modification without cross-reactions (Figure 2-1). 
 The first step of the synthesis of the functionalized PLA derivatives 2-5 involved 
the ring-opening co-polymerization of monomer 1 and l-lactide in the melt, followed by 
the Pd-catalyzed hydrogenation of the benzyl ether bonds to yield the hydroxyl-modified 
PLA derivative 2 (Appendix A). Polymer 2 was then used as the starting point for broad 
diversification of the functionalities using a number of post-polymerization 
modifications: (i) Reaction with 3-(diphenylphosphino)-4-(methoxycarbonyl) benzoic 
acid with N,N’-Dicyclohexylcarbodiimide (DCC)/4-Dimethylaminopyridine (DMAP) 
Figure 2-1: Fabrication of microparticles with orthogonally functionalized interfacial patches via EHD 
co-jetting. Functionalized PLA derivatives (1-5) are incorporated into different jetting solutions, leading 
to compartmentalized fibers, which can be sectioned into the corresponding microdisks. Each 
compartment surface establishes a unique surface patch that is then selectively modified via orthogonal 
reactions. 
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yielded the PLA derivative 3 for subsequent Staudinger Reaction. (ii) Alternatively, 
polymer 2 was converted with 2-(4-benzoylphenyl) acetic acid and DCC/DMAP under 
dry conditions to yield the photoreactive PLA derivative 4. (iii) Polymer 5, a 
cyclooctyne-modified polylactide, was derived from polymer 2 by straightforward 
conversion with 2-(cyclooct-2-yn-l-yloxy) acetic acid and DCC/DMAP. 
 In general, we found a satisfying compatibility of the PLA derivatives with the 
PLGA base polymer: For concentrations of up to 50% of the PLA additives, no adverse 
effect on the electrohydrodynamic co-jetting process was observed - independent of the 
chemical nature of the PLA derivative that was added to the jetting solutions. On the 
other hand, preliminary immobilization experiments demonstrated that PLA 
concentrations above 20% were adequate to ensure effective surface coupling of model 
ligands. 
 Next, we created a group of bicompartmental microparticles, which presented a 
single hemispheric patch of one of the functional anchor groups. In this case, the second 
hemisphere was comprised of the PLGA base polymer only and served as an internal 
reference for the surface reactions. Figure 2-2 depicts three different particle 
architectures. These architectures allowed for spatially controlled modification of one 
hemisphere only. The reference patch showed only very low levels of non-specific ligand 
adsorption. In Figure 2-2A, PLGA particles with one hemispheric surface patch 
containing polymer 3 (with green dye) was reacted with azide-PEG-Biotin (PEG: 
polyethylene glycol) via Staudinger ligation. The biotin was then labeled with TRITC-
StreptavidinTM (red dye) for imaging purposes. Co-existence of the red and green 
fluorescence in the CLSM images (Figure 2-2A3) confirms the spatially controlled  
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Figure 2-2: Selective surface modification of microparticles containing three different orthogonally 
functionalized PLA derivatives exclusively present in one hemisphere. In 2.A-C, microparticles 
displaying polymers 3 to 5 in one hemisphere only are selectively surface functionalized through 
Staudinger ligation (A), photo-immobilization (B), and alkyne/azide click chemistry (C). CLSM images 
show the spatioselective nature of the surface modifications. 
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surface modification of the microparticles. Similarly, Figure 2-2B displays particles with 
polymer 4 in the blue hemisphere only. As found for all PLA derivatives, the functional 
polymer is restricted to only one hemisphere of the microparticles (Figure 2-2B1) 
underpinning the high degree of patchiness obtained by the EHD co-jetting process. The 
microparticles were subsequently incubated with a protein, Bovine Serum Albumin 
(BSA)-Tetramethylrhodamine (red dye), and exposed to UV light at 365 nm to initiate 
the photo-immobilization of the BSA to the reactive surface patch (Figure 2-2B2). The 
high degree of selectivity of the photo-immobilization reaction is confirmed by the 
spatially controlled surface binding of the protein, as depicted in the overlay images of 
Figure 2-2B3. Similarly, the copper-free click chemistry of bicompartmental 
microparticles using polymer 5 was successfully carried out, as verified by CLSM 
analysis (Figure 2-2C). Here, the unreactive PLGA hemisphere was labeled with a green 
fluorescence dye loaded in the bulk of the compartment, whereas the azide-reactive 
compartment that contained polymer 5 was non-fluorescent (Figure 2-2C1). The spatially 
controlled surface modification of these patchy microparticles with azide-PEG-biotin and 
Alexa Fluor ® 647 StreptavidinTM (magenta dye) was confirmed by the selective surface 
binding shown in the overlay images of Figure 2-2C3. We further conducted selective 
surface modification of two-patch particles with one functionalized patch using both 
polymers 1 and 2 with analogue results (Figure 2-3). In summary, this initial 
immobilization studies indicated two important findings: (i) The addition of 
functionalized PLA derivatives into one jetting stream resulted in well-defined patchy 
microparticles and (ii) the selected surface chemistries are fully orthogonal to the base 
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polymer (PLGA), as evidenced by the fact that only negligibly low levels of non-specific 
binding were observed on the reference hemisphere.  
 Encouraged by these initial data, we conducted a second immobilization study 
that included two different functionalized PLA derivatives in two separate hemispheres 
of the same particle. For example, Figure 2-4 displays the CLSM, Raman 
characterization, and surface functionalization of these two-patch particles containing the 
two functional polymers 1 and 4 in separate compartments. To confirm that polymers 1 
and 4 were indeed localized in different hemispheres, rather than mixed throughout the  
Figure 2-3: The selective surface modification of bicompartmental microparticles containing polymer 1 
or 2 in one hemisphere.  In S.1A, the microparticles contain polymer 1 in the blue patch and PLGA in 
the green patch.  The carboxyl groups in polymer 2 are used to conjugate amine-PEG-Rhodamine (red) 
to the surface of one hemisphere using EDC/Sulfo-NHS chemistry.  In S.1B, the microparticles 
contained polymer 2 in the blue hemisphere and PLGA in the green hemisphere.  The hydroxyl groups 
in polymer 2 were used to attach carboxyl-PEG-Rhodamine using EDC/Sulfo-NHS chemistry. 
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entire particle, Raman confocal microspectroscopy was employed. This method can be 
used to gain chemical information of two and three-dimensional substrates and has been 
previously used to characterize Janus particles.72  Here, microparticles containing a 
low-molecular weight PLGA polymer with a higher number of free carboxylic acid end 
Figure 2-4: Selective surface modification of two-patch microparticles. Microparticles with chemically 
orthogonal polymers 1 and 4 in different hemispheres were characterized through Raman 
microspectroscopy (Figure 2-4.A), selectively surface-modified, and characterized using CLSM 
imaging (Figure 2-4B) 
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groups in one hemisphere and a mixture of PLGA and polymer 4 in the second 
hemisphere were imaged via Raman microspectroscopy (Figure 2-4A). In Figure 2-4A1, 
the two Raman spectra that were obtained from the two different hemispheres are 
compared. The spectrum obtained on the PLGA hemisphere is shown in red, while the 
spectrum obtained on the hemisphere displaying polymer 4 is indicated by a yellow color. 
The yellow spectrum further revealed characteristic bands indicative of polymer 4. 
Specifically, two additional bands at 1610 and 1660 cm-1 signify the presence of 
benzophenone groups (Appendix B-1). Therefore, the Raman maps shown in Figure 2-
4A3-5 unambiguously confirm that the PLGA base polymer is present in both 
hemispheres (red), whereas the PLA derivative 4 is restricted to one side only (yellow). 
Next, the two hemispheres were allowed to react with BSA-Tetramethylrhodamine (red 
dye) in the presence of UV light (first step) and amine-PEG-FITC (green dye) and 
EDC/Sulfo-NHS (second step). Here, the hemisphere containing polymer 4 
autofluoresces in the blue channel (Figure 2-4B3) to further distinguish the two 
compartments. Subsequent analysis with confocal laser scanning microscopy (CLSM) 
confirmed successful, yet highly selective surface modification of both surface patches 
(Figure 2-4B2-3). Taken together, the Raman microspectroscopic analysis and CLSM 
support the successful orthogonal surface reactions on these two-patch microparticles.  
 Beyond this particular combination of functionalized PLA derivatives, a number 
of different orthogonally substituted microparticles were prepared and selectively 
surface-modified, further elevating the potential scope of this novel approach. As 
depicted in Figure 2-5, two-patch microparticles containing polymer 2 (with blue dye) 
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and 5 (black, no dyes) in different hemispheres were prepared and the selective surface 
functionalization was demonstrated as well.  
 Further expanding on the complexity of possible multifunctional particles, we 
adapted our EHD co-jetting strategy to create three-patch microparticles. These particles, 
shown in Figure 2-6, contained patches displaying three different functionalized PLA 
derivatives, i.e., polymers 1, 4, and 5, respectively. As described above, it is important to 
ensure that the functionalized polymers are indeed localized in specific surface patches 
prior to conducting orthogonal surface modification. In fact, the defined localization of 
the reactive polymer species is an essential prerequisite for the spatially controlled 
surface modification. Figure 2-6A displays the results of the Raman microspectroscopic 
analysis of three-patch particles. The Raman spectra obtained from the three patches 
displayed characteristic bands of the PLGA base polymer (blue). In addition,  
Figure 2-5: The selective surface modification of bicompartmental microparticles containing polymer 2 
and 5 in separate hemispheres.  Here, the blue compartment contains polymer 2 and the black 
compartment (no dyes) contains polymer 5. The surface of the blue patch was first reacted with cooh-
PEG-Rhodamine through EDC/Sulfo-NHS chemistry, followed by the click reaction on the other 
hemisphere using the azide-PEG-biotin and the cyclooctynes present on the surface.  The biotins were 
then labeled with Alexa Fluor ® 647 Streptavidin for imaging purposes. 
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characteristic bands of polymer 4 at 1610 and 1660 cm-1 for benzophenone (black), and at 
2200 cm-1 for the cyclooctyne in polymer 5 (red) were selectively found in different 
surface regions, as shown in Figure 2-6A1 (Appendix B-2.) The two-dimensional 
reconstruction of the Raman spectra displays three distinct patches on these 
microparticles. The PLGA polymer is detected in the entire particle (blue, Figure 2-6A3), 
Figure 2-6: Characterization and selective surface functionalization of three-patch microparticles. 
Particles containing polymers 1, 4, and 5 in separate surface patches were characterized using Raman 
microspectroscopy (4.A). The surface of each patch was then selectively modified using orthogonal 
chemistries and analyzed through CLSM imaging (4.B). Unless noted, all scale bars are 5 µm. 
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while polymer 4 (white, Figure 2-6A4) and polymer 5 (red, Figure 2-6A5) are each 
restricted to two different surface patches. We further conducted a series of orthogonal 
surface reactions on these microparticles and analyzed them by fluorescence confocal 
microscopy. The schematic for the sequential chemistries and the results obtained by 
CLSM imaging are shown in Figure 2-6B1 and 2, respectively. Here, the blue patch, 
containing polymer 4, was functionalized by photochemical attachment of BSA-       
Tetramethylrhodamine(red dye), while the selective conjugation of azide-PEG-FITC 
(green dye) was restricted to the second surface patch that contained polymer 5. Efficient 
binding was achieved through click chemistry with the cyclooctyne groups of polymer 5. 
The third compartment, containing polymer 1, was reacted with amine-PEG-Biotin 
through EDC/Sulfo-NHS chemistry and labeled with Alexa Fluor ® 647 StreptavidinTM 
(magenta dye) for CLSM imaging.  
 Figure 2-6B3 shows the three-dimensional reconstruction of the microparticles on 
the basis of the fluorescence images collected in the z-direction. The particles were 
imaged in the xy-plane with a step size of 250 nm and were then reconstructed to display 
the three-dimensional structure and characteristics of the patchy microparticles. We note 
that these results correspond well with the cross-sectional view (Figure 2-6B3 right 
image).  
 
Applications of Established Techniques: Incorporation of Stealth & Targeting Moieties 
into Surface Patches of Particles  
 The ability to selectively surface modify various patches on the surface of 
particles is especially important in drug delivery applications, where the incorporation of 
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stealth and targeting moieties can determine the length of time the particles circulate in 
the blood stream and their specificity towards their selected target.2, 9 Polyethylene glycol 
(PEG) is a well-established ‘stealth’ group in this field. PEG can enhance the circulation 
duration of particles in the body by creating a hydrophilic layer on the surface of the 
particles that repel the attachment of plasma proteins (opsonization) and delay the 
clearance of particles via the MPS (Mononuclear phagocyte system).1 As a result, here 
we have explored the incorporation of PEG on the surface of multifunctional particles in 
select patches. In addition to long circulation, the targeting molecules used play a crucial 
aspect on the fate of the particles in the body and the attachment of two targeting 
molecules, folic acid and iRGD, are demonstrated. Folic acid receptors are overexpressed 
in cells in a number of tumors and decorating the surface of particles with folic acid will 
potentially enhance the uptake of particles by tumor tissue.135 In addition to targeting to 
the tumor, in most cases (especially in solid tumors), the particles also need to penetrate 
through the different layers of the tumor to successfully eradicate it entirely. To this end, 
Professor Ruoslahti’s group have discovered a tumor homing and penetrating peptide 
(iRGD) that is capable of not only targeting to the tumor site, but also penetrating through 
the different layers of solid tumors.136 
            Initially, we used particles with two distinct compartments, each with a different 
functional polymer, to attach stealth (PEG) and targeting (folic acid) groups on separate 
patches of the particles. Here, folic acid was chosen as a model targeting moiety in a 
proof of concept study. The particles contained polymer 666 in one compartment and 
polymer 2 in the second compartment (Figure 2-7). The schematic explains the steps 
taken to functionalize each surface separately: the alkyne groups in polymer 6 were first 
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used to attach azide-mPEG via click chemistry to one patch, followed by the attachment 
of carboxyl-PEG-Folic Acid or carboxyl-PEGm via EDC/sulfo-NHS chemistry to the 
second patch. To demonstrate the attachment of the folic acid, primary and secondary 
antibodies specific to folic acid were used (Figure 2-7b). Here, the particles with PEG on 
both sides were used as a control to determine the specific attachment of the antibodies. 
As shown, the particles containing a patch of folic acid were labeled with the antibody 
(red on one surface, Figure 2-7b), while the control group did not have any antibody 
attachment (Figure 2-7c). 
 
Figure 2-7: Attachment of PEG and folic acid to separate patches of particles. (A) Schematic of steps 
taken for the attachments. (B) CLSM image of particles containing folic acid and labeled with 
antibodies (red). (C) CLSM image of particles without folic acid and incubated with the same 
antibodies.  
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 In addition to attaching a single functional moiety to a surface patch, we were 
interested in exploring the possibility of attaching multiple functionalities to the same 
patch. In multi-compartmental particles, this technique would enhance the functionalities 
per particle, where multiple targeting ligands and stealth groups at specific ratios could be 
evaluated for their targeting capabilities. Here a bi-functional polymer (7) containing both 
alkyne and acrylate groups at a 9:1 ratio was used (Figure 2-8). The polymer was 
incorporated into one compartment, while the second compartment was composed of neat 
PLGA and served as the control (Figure 2-8a). The particles were first reacted with azide-
PEGm via copper catalyzed click chemistry to impart stealth functionalities, followed by 
Figure 2-8: Dual orthogonal chemistries on a single particle patch. (A) Using polymer 7, the attachment 
of azide-mPEG  via copper catalyzed click chemistry and thiol-iRGD-FITC via thiolene click chemistry 
on the same patch are demonstrated. (B) CLSM images of particles showing the attachment of PEG and 
iRGD (green) to one side. 
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the thiolene click reaction of thiol-iRGD-FITC to attach a tumor homing and penetrating 
peptide to the particles. Using CLSM imaging, the incorporation of the FITC labeled 
iRGD can clearly be observed (Figure 2-8b).  
 This data, in addition to the previous figure showing the orthogonal attachment of 
targeting and stealth groups on distinct patches, demonstrate the capabilities of our 
system for the precise incorporation of a variety of targeting groups (small molecules, 
peptides, antibodies, etc.) and stealth moieties. Such systems can be used for the 
development of particles with multiple functionalities and can create a platform for the 
testing of the effect of multivalency and avidity on particle targeting.137 
 
Applications of Established Techniques: Magnetic Self-Assembly of Anisotropic Disks 
 In addition to using multifunctional particles for drug delivery applications, 
anisotropic particles with distinct patches can also be used for various self-assembly 
applications. Here, we were interested in combining our well-established chemically 
orthogonal patchy particles with stimuli-responsive particles towards an external 
magnetic field to create self-assemblies of particles with unique architectures (Figure 2-
9). Similar to the last section, fibers were fabricated using the EHD co-jetting system and 
were sectioned into microdisks. In this case, the microdisks contained iron oxide 
nanoparticles (Ocean Nanotech LLC, 30 nm) in select compartments that enabled the 
microdisks to be responsive to an external magnetic field. We were interested in 
exploring the alignment of such microdisks, expanding on the above mentioned surface 
patch work to include double click chemistries on distinct patches, and using a 
combination of these techniques to create unique self-assemblies of particles.  
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 To begin, the responsiveness of microdisks with iron oxide nanoparticles in one 
compartment to an external magnetic source was explored (Figure 2-10). This work was 
done by Dr. Sangyeul Hwang, where it was observed that the particles aligned based on 
the applied magnetic field (Figure 2-10A, where B is the magnetic field and theta is the 
angle between the magnetic field and the normal to the loop of the area encapsulated in 
the field based on Farayday’s law of electromagnetic induction). As the particles aligned 
in the direction of the magnetic field and moved toward the external magnet, they self-
assembled into the structures seen in Figure 2-10B. At the removal of the magnetic field, 
the particle disassembled into individual, un-aligned particles.  
 
 
Figure 2-9: Schematic demonstrating the fabrication of the fibers via EHD co-jetting and subsequent 
sectioning into microdisks; the exploration of selective surface modifications and alignment of the 
particles to an external magnetic field; and the combination to yield self-assemblies of particles. 
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 For this application, we were also interested in expanding our multipatch particles 
to include double click surface reactions. Such capabilities could be used to connect the 
particles in the structures seen in Figure 2-10 to make stable self-assembled entities, as 
well as potentially assemble them into hierarchical structures. To this end, particles 
containing polymer 5 and 6 were fabricated according to the above mentioned 
techniques. Both sides are reactive towards azide-containing molecules, however, while 
polymer 5 can react by simple incubation, polymer 6 requires the addition of a catalyst to 
complete the reaction. This was used to our advantage to create orthogonal double-click 
particles (Figure 2-11). The particles were first reacted with azide-PEG-FITC via copper 
free click chemistry with polymer 5, followed by incubation in excess azide-PEGm to 
ensure all functional cyclooctyne groups were reacted. After washing away all unreacted 
material, the particles were then incubated with azide-PEG-biotin and a catalyst (copper) 
to react with the alkyne groups in the second compartment. The particles were then 
incubated in Alexa Fluor ® 647 StreptavidinTM to label the biotin groups. As seen in  
Figure 2-10: The responsiveness of microdisks to an external magnetic field. (A) The particles align 
according to the magnetic field and (B) move toward the external magnet. During this process, they 
assemble into structures of alternating compartments. 
	   43 
 
Figure 2-11, the surface modifications yielded orthogonal patches on two separate 
hemispheres of the particles.  
 Expanding on this technique, tricompartmental particles with polymers 1, 5, and 6 
were fabricated and surface modified (Figure 2-12). Here, the same procedure as for 
bicompartmental particles in Figure 2-11 were followed, but in between the two click 
chemistry steps the particles were incubated with amine-PEG-Rhodamine to react with 
the carboxyl groups of polymer 1 via EDC/Sulfo-NHS chemistry. This resulted in 
microparticles with three distinct surface patches.  
 By combining these two techniques, self assembly of particles in a magnetic field 
and the creation of reactive patches on microparticles, one could fabricate permanent 
self-assemblies of microparticles in unique architectures using a bottom-up approach. For 
example, if the compartment containing the iron oxide nanoparticles also contains  
Figure 2-11: Orthogonal surface modifications using dual click chemistry on the same particle. The 
particles were first reacted with azide-PEG-FITC via copper free click chemistry with polymer 5, 
followed by a reaction with azide-PEG-biotin and the respective labeling via copper catalyzed click 
chemistry with polymer 6. 
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polymer 5, the self-assembled particles under the magnetic field can be cross-linked 
together using a bi-azide molecule via copper free click chemistry with the cyclooctynes 
in polymer 5 (during the assembly the compartments with iron oxide are typically next to 
each other as they are attracted to each other). Upon the removal of the magnetic field, 
these structures would retain their assembled geometries and can be used for further 
Figure 2-12: Particles with three distinct surface patches. Tri-compartmental particles with distinct 
functional polymers in each compartment were sequentially reacted to create particles with multiple 
patches. 
	   45 
designs. Higher ordered entities could potentially be created from these structures if the 
second compartment contains another functional polymer that can be used to further 
connect the structures together.  
 Here, we demonstrate the fabrication of permanent self-assembled structures from 
anisotropic building blocks as a first proof of concept study (Figure 2-13). Particles 
containing polymer 5 and iron oxide nanoparticles in one compartment were fabricated 
based on the previous mentioned techniques. The particles were aligned in an external 
magnetic field and incubated with azide-PEG-azide. As the particles move in the 
magnetic field and assemble, the compartments containing polymer 5 and iron oxide 
nanoparticles (blue) come together and are cross-linked via the azide-PEG-azide 
Figure 2-13: The self-assembly of anisotropic particles into permanent structures. (A) Particles 
containing polymer 5 and iron oxide nanoparticles are aligned in a magnetic field, cross linked using 
azide-PEG-azide, and their stability under varying magnetic field directions is shown. (B) Longer self-
assembled permanent structures and their three-dimensional reconstruction.  
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molecules through copper free click chemistry with the cyclooctynes in polymer 5. 
Figure 2-13A demonstrate the stability of these particles under varying directions of the 
external magnetic field (arrow pointing up signifies an upward magnetic field and the ‘x’ 
signifies a magnetic field pointed into the page). Looking at longer assemblies of these 
structures (Figure 2-13B), it can clearly be seen that the particles are assembled in a semi-
chiral orientation around an axes, which in this case is the blue connecting compartment. 
This can also be seen in the three-dimensional reconstructions of these particles.   
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2.4 Summary 
 
 In conclusion, we have demonstrated a novel approach towards microparticles 
with fully orthogonal surface patches that takes advantage of a combination of novel 
chemically orthogonal polylactide-based polymers and their processing via 
electrohydrodynamic co-jetting to yield unprecedented multifunctional microparticles. 
These and other microstructured particles are highly sought after for their potential to 
present multiple distinct ligands in a directional manner. Applications may range from 
novel gels and particle self-assembly to use as carriers for cancer therapies with 
synergistic targeting effects from complementary ligands. For many of the above-
mentioned applications, smaller particles are required. While designed as a proof-of-
concept study to establish the feasibility of orthogonal reaction strategies on multivalent 
particles, future work will need to focus on refining critical particle characteristics, such 
as size or shape, while maintaining the same precision with respect to 
compartmentalization and spatially controlled surface modification. However, we have 
already shown that simpler versions of multi-patch particles can be made as small as 200 
nm.43 It is thus plausible that future work can access similar size ranges with the type of 
orthogonal multi-patch particles described in this study. 
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CHAPTER 3 
Programming Physical Properties of Particles 
 The material in this chapter has been adapted with minor modifications from the 
following articles: 
(1) S. Rahmani, T.-H. Park, A. F. Dishman, J. Lahann, “Multimodal Delivery of 
Irinotecan from Microparticles with Two Distinct Compartments”, J. Control. 
Release, 2013, 172, 239-245. 
(2) S. Rahmani, A. F. Dishman, R. Hartmann, A. C Misra, W. Parak, J. Lahann, 
“Multicompartmental Nanoparticles and Their Characterizations”, In preparation 
 
 
3.1 Motivation and Background 
 
 In addition to surface properties, the physical properties of a carrier system can 
have profound influence over its fate in the body and the overall outcome of the 
treatment.2 Extensive studies have demonstrated that physical properties, such as size, 
shape, texture, and charge can control carrier half-life, targeting, cell interactions, 
metabolism, and excretion from the body.138 For example, the size of particles can affect 
drug loading, protein interactions that can increase/decrease the rate of opsonization, cell 
interactions with the MPS that could lead to lower/higher uptake and longer/shorter 
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circulation times, employ passive targeting using the enhanced permeation and retention 
(EPR) effect, or control the rate and extend of tumor penetration.1, 9 On the other hand, 
the shape of particles can affect cellular uptake, flow dynamics in the blood, penetration 
into tumors, and excretion from the body.139, 140 Due the importance of physical 
characteristics on the functional abilities of a carrier system, this chapter focuses on 
developing strategies for controlling such properties.  
 
 
3.2 Experimental Methods 
 
3.2.1 Materials 
 Dextran, chloroform, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 
pyridinium p-toluenesulfonate, 2-methoxypropane triethylamine, acetic acid, sodium 
acetate, phosphate buffered saline (PBS), poly[tris(2,5-bis(hexyloxy)-1,4-
phenylenevinylene)-alt-(1,3-phenylenevinylene) (PTDPV), poly[(m-phenylenevinylene)-
alt-(2,5-dihexyloxy-p-phenylenevinylene)] (MEHPV), ethyl amine, bromoacetyl 
bromide, dimethyl amino pyridine, benzyl alcohol, l-lactide, tin (II) ethyl hexanoate, 
anhydrous toluene, palladium 10% wt. on activated carbon, anhydrous tetrahydrofuran 
(THF), N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), and 
tween 20 were used as purchased from Sigma Aldrich, USA. Polylactide-co-glycolides 
(PLGA) with ratios of 50:50 lactide to glycolide and a molecular weight of 17 or 44 kDa 
was purchased from Lactel Corporation. Irinotecan was purchased from Ontario 
Chemicals and O-benzyl-L-serine was purchased from Alfa Aesar.  Sulfuric acid, 
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acetonitrile, sodium nitrite, dichloromethane, sodium carbonate, N-
hydroxysulfosuccinimide (Sulfo-NHS), and acetone were purchased from Fisher 
Scientific. Diethyl ether was purchased from Acros Organics. Hydrogen was provided by 
Cryogenic Gases.  
 
 
3.2.2 Fabrication of Particles with Various Shapes. 
 
 Particles with various shapes (rods, RBC shaped, & flat disks) were fabricated 
through the EHD co-jetting technique by changing different parameters such as 
concentration, flow rate, and molecular weight of the jetting solutions. Specifically, RBC 
shaped particles were jetted using a PLGA 85:15 (50-75 kDa) at a concentration of 7% 
w/v and a flow rate of 1 ml/hr. Flat disks were jetted using the same polymer but at a 
lower concentration of 4% w/v and a flow rate of 0.6 ml/hr. Rods were fabricated using a 
lower molecular weight PLGA (50:50, 17 kDa) at a concentration of 5% w/v and a flow 
rate of 0.1 ml/hr. 
 
 
3.2.3 Fabrication of Particles with Controlled Texture. 
  
Fabrication of Particles with Different Degrees of Roughness 
 Particles with the same jetting formulation (for RBC shaped particles) were jetted 
in different environments with increasing levels of humidity.  
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Fabrication of Porous Particles  
 Acetal-modified dextran (polymer 8) was synthesized as previously described by 
Fréchet, et al. The synthesis and analysis of the polymer was graciously done by Dr. Tae-
Hong Park. The polymer was analyzed via IR and NMR spectroscopy to confirm the 
presence of the appropriate functional groups and polymer purity. The analysis for the 
degree of protection and cyclic vs. noncyclic protection was done through NMR analysis. 
Jetting solutions used were a 97:03 ratio of chloroform to DMF and a polymer 
concentration of 15% w/v. For compartments that contained polymer 8, 75% w/w of the 
total polymer was polymer 8 while the rest was PLGA. Microparticles containing 
polymer 8 in one compartment were tested for dextran deprotection and release in acidic 
and neutral conditions at physiological temperatures.  
 The neutral buffer (pH 7.4) used was PBS and the acidic buffer (pH 5) is a 
mixture of acetic acid and sodium acetate.141 Both buffers contained 1% Tween 20 (v/v). 
Different aliquots were tested via the Bicinchoninic Acid (BCA, ThermoScientific) test to 
determine the amount of dextran released. 
To impart porosity, fabricated anisotropic microparticles were suspended in 
neutral or acidic buffers, filtered through a 10 µm filter mesh, and placed in a 37oC 
incubator. Samples were taken every five hours, washed 3-5 times with DI water, and 
imaged via SEM. Microparticle diameter measurements were done using Image-J 
software. More than 150 microparticles were measured per sample.   
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3.2.4 Fabrication of Particles with Controlled External Charge 
 
 Particles containing polymer 8 (acetal dextran) were fabricated according to 3.2.3. 
Particles containing polymer 2 (3-Hydroxyl PLGA), were jetted with a 10% w/v solution 
at 0.4 ml/hr, where the percentage of polymer 2 in one compartment was increased from 
zero to 100%. To determine the surface charge of these particles, each set was dispersed 
in DI water with 0.01% Tween 20 (v/v) and their zeta potential was measured with a 
Malvern Zetasizer in triplicates.  
 
 
3.2.5 Fabrication of Nanoparticles and Their Separation via Centrifugation 
  
 Nanoparticles were fabricated using a 17 kDa PLGA (50:50) at 10% w/v with 
different solvent ratios of chloroform and DMF. The addition of cetyl 
trimethylammonium bromide (CTAB) at 5% w/v was used in some cases to reduce the 
size of the particles. The flow rate used was 0.1 ml/hr. To separate the particles into 
uniform size ranges, serial centrifugation at 9400 RCF and at various durations (1, 10, 20, 
and 30 minutes) was used to isolate specific size ranges. 
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3.2.6 Determining Ligand Density on the Surface of Nanoparticles 
 
 Nanoparticles containing polymer 6 at 25% w/w, PLGA at 75% w/w, and CTAB 
at 5% w/v with a solvent ratio of 97:3 Chloroform:DMF were fabricated and separated 
into monodispersed 100 nm nanoparticles. The nanoparticles were analyzed with 
Nanosight to determine their size distribution and concentrations, and thereby their 
effective surface area. The particles were then incubated with 0.01, 0.1, or 1 mg of azide-
PEG-FITC to react with the alkyne groups on the particles via copper catalyzed click 
reaction. The unreacted material was removed from the sample after centrifugation to 
pellet the particles, and was measured using a UV visible Spectroscopy. The 
concentration of the unreacted material was determined using a calibration curve with the 
azide-PEG-FITC. 
 
 
3.2.7 Nanoparticle for Biodistribution Studies 
  
 Nanoparticles were fabricated using a phenol-containing polymer (poly (4-
vinylphenol-co-methyl methacrylate) (25% w/w), PLGA 40 kDa (50% w/w), and 
polymer 6 (25% w/w) to make particles that had dual functionalities. The flow rate used 
was 0.1 ml/hr. After fabrication, the nanoparticles were collected in PBS and 1% v/v 
Tween 20, separated via centrifugation (10 min samples were used), and PEG-ylated 
using an azide-PEG eight arm star (40 kDa, 10 mM) via copper catalyzed click 
chemistry. The particles were analyzed via DLS & Nanosight to determine their size 
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distribution & concentration. The nanoparticles were radiolabeled with I125, purified, and 
then injected intra-orbitally into mice by the Muzykantov group at the University of 
Pennsylvania. Animals were sacrificed at 1, 4, and 24 hours and the biodistribution of the 
nanoparticles in the specific organs were measured using a TCA assay and a Wallac 1470 
Wizard gamma-counter, as previously published by Muzykantov, et. al.142 
 
 
3.2.8 Fabrication of Hydrogel Nanoparticles 
 
 Hydrogel nanoparticles composed of human albumin and PEG were fabricated 
using the EHD co-jetting technique. The solutions used were a human albumin 
concentration of 2.5% w/v; 10-30% w/w NHS-PEG-NHS as the crosslinker; and DI 
water and ethylene glycol as the solvents at a ratio of 4:1. After jetting, the particles were 
incubated in a 37oC incubator for a week to ensure complete crosslinking of the albumin 
and NHS-PEG-NHS, before collecting them in DI water or PBS for further analysis. The 
size distribution of the dry particles was analyzed based on SEM images (ImageJ), and 
their size distribution in various solvents (DI water, PBS, and pH 5 buffers) were done 
using DLS and Nanosight analysis. 
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3.2.9 Fabrication of Nanoparticles for Potential Self-Assembly Applications 
 
 Nanoparticles with PMMA (poly (methyl methacrylate), 15 kDa), PtBMA (poly 
(tert-butyl methacrylate), 20 kDa), and biphasic particles with each polymer in a separate 
compartment were fabricated via EHD co-jetting. The concentrations and solvents used 
for each are as follows: i) PMMA nanoparticles with 5% w/v polymer, 2.5% w/v CTAB, 
7:3 ratio of chloroform: DMF, and a flow rate of 0.1 ml/hr; ii) PtBMA nanoparticles with 
5% w/v polymer, 2.5% w/v CTAB, 8.5:1.5 ratio of chloroform: DMF, and a flow rate of 
0.1 ml/hr; iii) PMMA/PtBMA Janus particles by using each formulation separately in a 
distinct compartment. The nanoparticles were collected in DI water, separated via 
centrifugation (4000 RPM for 6 hours), and their size distribution and concentration were 
analyzed with DLS and Nanosight.  
 
 
3.3 Results and Discussion 
  
Fabrication of Particles with Various Shapes 
 The fabrication of particles with programmable physical properties were done by 
changing the various EHD co-jetting parameters, such as polymer molecular weight & 
concentration, flow rate, dielectric constant, viscosity, surface tension, external humidity, 
and the incorporation of charged species. To begin, we were interested in the fabrication 
of particles with a diverse set of shapes as this property has been well-established as a 
major factor in cellular uptake and clearance from the body.139, 140 As demonstrated in 
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Figure 3-1, particles geometries including flat disks, red blood cell (RBC) shaped 
particles, and rods were fabricated by changing the concentration, flow rate, and 
molecular weight of the polymers use. To fabricate flat disks, PLGA 85:15 with a 
molecular weight of 50-75 kDa was used at a concentration of 4% w/v with a rapid flow 
rate of 0.6 ml/hr. As a comparison, using the same polymer at a 6.5% w/v concentration 
and 0.2 ml/hr has previously been shown to result in microspheres.68 The change from 
microparticles to flat disks occurs due to the lower concentration of the polymer used 
(less chain entanglement) and the high flow rate, which results in the droplet’s non-
uniform drying procedure. Here, an outer solid layer of polymers on the surface of the 
Figure 3-1: Particles with various shapes were fabricated. (A) SEM images of RBC particles (A-1 & 2) 
and their corresponding size distributions (A-3). (B) SEM images of flat disks (B-1 & 2) and their 
corresponding size distributions (B-3). (C) SEM images of rods and their corresponding size 
distribution where the blue represents the diameter measurements of the rods and red their 
corresponding length (C-3). The average size and standard deviation for each sample is also listed. All 
size measurements were done based on SEM images using ImageJ analysis.  
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particles is first formed before the solvents in the center have evaporated, thereby 
creating a void in the center. This together with the high flow rate means that the droplets 
contact the substrate before they are uniformly dried, which results in their collapse into a 
disk at the point of contact.68 For RBC shaped disks, a higher concentration of the same 
polymer (7% w/v) at a higher flow rate (1 ml/hr) were employed. Here, due to the higher 
concentrations, the particles have the chance to partially form into a sphere, but again, 
due to the high flow rate they undergo non-uniform evaporation throughout the particles 
and form into RBC shaped particles upon contact with the substrate. For fabrication of 
rods, a low molecular weight PLGA polymer (17 kDa) at a concentration of 5% w/v with 
a low flow rate of 0.1 ml/hr was used. The low molecular weight and concentration of the 
polymer together yielded a solution with low chain entanglement between the polymer 
chains, which would then not have enough time to form into individual droplets from the 
ejected stream connecting the droplets before the rapid evaporation of the solvents, thus 
forming rods instead. The shapes of each set of particles were observed with SEM 
imaging (Figure 3-1 A-C1&2) and their size distribution and average size and standard 
deviation were determined using ImageJ analysis. For the rods, the diameter and the 
length of the particles were both quantified. 
 
Fabrication of Particles with Different Textures 
 In addition to controlling the shape of the particles, we were also intrigued by the 
possibility of controlling the texture of such particles due to its influence in carrier-cell 
interactions. Here, we have explored establishing control over the texture of the particles 
in terms of the surface roughness and the degree of porosity in the particles. An aspect to 
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consider in fabricating such particles is the effect of the external environment, especially 
humidity, on the composition of the particles (Figure 3-2). When keeping other 
parameters such as solutions used, flow rates, applied voltage, and environmental 
temperature constant, an increase in the humidity resulted in particles with a ‘rough’ 
surface (Figure 3-2B). The same solution jetted at a lower humidity resulted in smooth 
particles (Figure 3-2A). Having a higher percentage of humidity in the air reduces the 
rate of evaporation of the solvents used in the jetting solutions and the non-uniform 
evaporation results in the non-energetically favorable rough surfaces.  
  
 In addition to fabricating particles with rough surfaces, the fabrication of porous 
particles was also explored. Unmodified dextran polymers are water-soluble 
polysaccharides that have been used extensively in many biomaterial applications.143 It is 
this water-solubility, however, that limits the broader use of dextran for drug delivery and 
tissue engineering, because drug carriers, implants, or scaffolds fabricated from dextran 
will dissolve in water within a matter of minutes.144 Masking of the hydroxyl groups on 
Figure 3-2: Fabricating particles with rough surface properties. The same jetting solution was used for 
both particle sets and the only variable used was an increase from 30.6% humidity (A) to 40.7% 
humidity (B) that resulted in particles with rough surfaces. 
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the backbone of the dextran polymer can render this polymer water-insoluble and thereby 
increase its applicability in this field. Depending on the type of chemistry used, this 
protection can be pH-responsive and, in so doing, a polymer that can be water soluble or 
insoluble upon demand can be synthesized.141, 145, 146 In addition to PLGA, we have 
employed polymer 8, as a pH responsive polymer that is water-insoluble at physiological 
pH, but water-soluble in acidic environments.141 This change in solubility is caused by 
the hydrogen-catalyzed cleavage of the acetal groups that chemically protect the hydroxyl 
groups of the unmodified dextran (Figure 3-3). Here polymer 8 can potentially be used in 
the fabrication of pH sensitive carriers that can respond selectively to specific 
physiological or pathophysiological cues such as the extracellular matrix surrounding 
tumors or inflamed tissue.147, 148 Such possible applications of this polymer are further 
Figure 3-3: Particle fabrication procedure and hypothesized structure of particles depending on pH of 
environment.  The table contains the polymer characterization information of polymer 8. 
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explored in Chapter 4 of this dissertation. 
Polymer 8 was synthesized according to previously published procedures141 and 
characterized by NMR analysis. Based on this analysis, approximately 75% of the 
hydroxyl moieties of the polysaccharide were protected with acetal groups. Among the 
protected moieties, the ratio of cyclic to non-cyclic units was approximately 1.1:1. This 
degree of protection resulted in a polymer that was water-insoluble in physiological pH, 
while retaining some of its polar characteristics due to the small amount of free hydroxyl 
groups present.  
 Upon confirmation of the polymer structure and characterization, we focused on 
the preparation of anisotropic microparticles from these polymer systems using the EHD 
co-jetting technique as described in Chapter 1 of this dissertation. To demonstrate this, 
we first fabricated bicompartmental microparticles containing a mixture of polymer 8 and 
PLGA in the same compartment. The bicompartmental microparticles containing 
polymer 8 were characterized by Confocal Laser Scanning Microscopy (CLSM) and 
Scanning Electron Microscopy (SEM), as demonstrated in Figure 3-4. The CLSM 
images indeed confirmed the bicompartmental geometry of the microparticles, which 
contained a “green” fluorescent dye (PTDPV) in the first compartment (Figure 3-4A) and 
a “blue” fluorescent dye (MEHPV) in the second (3-4B) compartment. Figure 3-4C is an 
overlay image of the two channels confirming that the dyes do not mix and that the 
microparticles are, therefore, composed of distinct compartments. The three-dimensional 
shape and size distribution of the microparticles was assessed by SEM (Figure 3-4D). 
Using the Image-J analysis software 149-151, it was found that the as-jetted microparticles  
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are approximately 8.4 ± 0.07 µm in diameter on average, with few, larger microparticles 
at 10-15 µm that were easily removed via filtration.    
 To verify the anisotropic nature of these microparticles and their ability to 
selectively respond to environmental changes, microparticles were incubated in two 
different pH environments, pH 5 and pH 7.4, at physiological temperatures and the 
release of free dextran and its effect on the structure of the microparticles was quantified. 
As illustrated in Figure 3-5, release of dextran was observed at acidic pH, while no 
dextran was released at pH 7.4, indicating that soluble dextran is released only in the 
acidic environment. The small burst release observed in the pH 7.4 sample is most likely 
due to a small fraction of polymer 8 with a lower level of protection that can make this 
polymer water soluble. Overall, these results confirm that a differential release of water-
soluble dextran from our microparticles can be achieved.    
Figure 3-4: Characterization of microparticles containing polymer 8 + PLGA in one compartment and 
PLGA in the other compartment. A.-C.) Confocal images of the particles, where A.) is the blue channel 
(PLGA compartment), B.) is the green channel (PLGA + polymer 8 compartment), and D.) is the 
overlay of the two images.  E.) SEM image of the particles showing their three-dimensional shape and 
size. 
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 To quantify the effect of dextran release on the structure of the microparticles, 
filtered microparticles (to remove a small fraction of larger microparticles) were 
incubated in two different pH environments (pH 5 and pH 7.4) at physiological 
temperatures and their degradation kinetics were monitored via SEM imaging (Figure 3-
6). The initial dextran release studies (Figure 3-5) confirmed that the release of dextran 
was completed within 10 hours of incubation. Hence, the appearance of pores due to this 
release should be observed within that period, followed by rapid bulk degradation of the 
rest of the compartment (now composed of PLGA) due to the porous remaining network. 
Pores were observed within the first 10 hours of incubation: within 5 hours (Figure 3-6B) 
small pores covered one half of the microparticles in comparison to the control at pH 7.4 
(Figure 3-6F). After 10 hours, larger pores were observed (Figure 3-6C), as all of the 
dextran was released. By this time, the size of the microparticles had also decreased and 
Figure 3-5: Release of dextran from bicompartmental microparticles.  The release at two pH values, pH 
5 and 7.4, are displayed. 
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bulk erosion of the PLGA material had begun. After 15 hours (Figure 3-6D) very few 
pores could be seen as most of the porous compartment had eroded away. Complete 
degradation of one side was observed within 20 hours (Figure 3-6E). In comparison, the 
same microparticles incubated at pH 7.4 for 20 hours (Figure 3-6F) remained intact and 
were approximately twice the size of those incubated for the same period in the acidic 
environment.   
 In order to quantify the results and confirm the complete and exclusive 
degradation of one compartment, the size of the microparticles as a function of time was 
Figure 3-6: Characterization of polymer 8 containing microparticles in two different pH environments.  
A.-F.) SEM images of the microparticles over time in pH 5 and 7.4. G.) Change in the microparticle 
diameter over time based on ImageJ analysis. 
	   64 
quantified using Image-J software 149-151. The measurements were done based on SEM 
images taken of the microparticles at zero, 5, 10, 15, and 20 hours for both pH 5 and 7.4 
incubations. As seen in Figure 3-6G, the pH 7.4 samples were consistent in size 8.29 ± 
0.07 µm, while the pH 5 samples decreased to approximately 60% of their original size 
5.18 ± 0.06 µm. Based on this analysis, as well as the SEM images, we have 
demonstrated the fabrication of anisotropic microparticles and control on the selective 
porosity of one compartment through stimuli responsive chemical degradation.       
 
Fabrication of Particles with Controlled External Charge 
 To fabricate particles with an external charge hydrophilic polymers 2 and 8 were 
incorporated into the particles and their zeta potential measurements were measured. The 
hydrophilicity of polymer 8 can be attributed to the residual hydroxyl groups; while most 
hydroxyl groups are protected (75%), the polymer still retains enough free hydroxyl 
Figure 3-7: Zeta potential measurements of PLGA and PLGA + Polymer 8 containing microparticles. 
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groups to make the surface of the microparticles hydrophilic. This assumption was 
further supported by zeta potential measurements, which allowed for approximating the 
surface charge of the bicompartmental microparticles. The graph in Figure 3-7 displays 
the differences in surface charge between pure PLGA microparticles and polymer 8 
containing microparticles. PLGA microparticles have a zeta potential of -4.5 ± 1.2 mV, 
while polymer 8 containing microparticles have a more negative zeta potential 
measurement of -15.6 ± 2.1 mV. These results confirm that the polymer 8 containing 
microparticles are more hydrophilic and polar than PLGA microparticles due to the free 
hydroxyl groups present on their surface.  
 Similarly, particles containing polymer 2 with free hydroxyl groups were 
fabricated using the EHD co-jetting system. Three sets of particles with 0, 50, and 100% 
w/w of polymer 2 in one compartment and PLGA in the other compartment were jetted 
and their zeta potentials were measured. A decreasing level of zeta potential was 
observed for particles sets with increasing amounts of polymer 2 incorporation, as 
Figure 3-8: Zeta potential measurements of PLGA and PLGA + Polymer 2 containing microparticles. 
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expected (Figure 3-8). As a result, the control over the external charge of the particles 
depending on the polymers used was established using two types of functional polymers. 
 
Fabrication and Analysis of Nanoparticles 
 Size is an important physical parameter for particles used in drug delivery 
applications due to their influence over circulation times, rates of opsonization, cellular 
uptake, passive targeting to tumors via the EPR effect, tumor penetration, and excretion 
from the body.138  In the EHD co-jetting system several parameters, such as polymer 
molecular weight & concentration, solvent viscosity & dielectric constant, and applied 
voltage control the size and uniformity of particles ranging from micro- to nano-meters in 
diameter. One of the most common routes of fabricating nano-particles and -fibers 
through electro-spraying and -spinning, respectively, is the use of dilute polymer 
concentrations.152 Accordingly, to fabricate nanosized particles using the EHD co-jetting 
technique, various solutions with dilute concentrations of a low molecular weight PLGA 
(4.1 kDa) were jetted (Figure 3-9). Based on these studies nanoparticles as small as 100-
200 nm could be fabricated. However, due to the dilute concentration used, the yield of 
the nanoparticles were extremely low (as a reference, the images shown in Figure 3-9 
were taken after 4-10 hours of jetting on the same substrate, where typically the entire 
sheet is covered with particles after approximately 30 minutes). As a result, other routes 
of fabricating nanoparticles were explored. 
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 The other parameters investigated for the fabrication of nanoparticles include the 
use of solvents with higher dielectric constants and surface tensions and the incorporation 
of charged species, which affected the dielectric constant and overall charge of the jetting 
solutions. The effect of each of these parameters, using the same polymer (PLGA 50:50, 
17 kDa) and at the same concentration of 10% w/v, on particle size and their combined 
effect were subsequently studied. It was observed that a solvent ratio of 97:3 chloroform: 
DMF yielded polydispersed microparticles (Figure 3-10A), while the same solution with 
a solvent ratio of 1:1 chloroform: DMF yielded bimodal, yet uniform particles with one 
set of particles at approximately 50-150 nm and a second set at approximately 1 µm 
(Figure 3-10B). Alternatively, keeping the same ratio of solvents (97:3) but adding a 
Figure 3-9: PLGA nanoparticles fabricated through the EHD co-jetting technique. PLGA 
concentrations of 1, 0.5, and 0.03% w/v in DMF (A-C respectively) were sequentially tested to 
determine the lower particle size range. (D) The DLS measurement of the nanoparticles in (C) were 
taken, which show an average diameter size of approximately 250 nm. This is larger than the observed 
size in the SEM images and is most likely due to aggregation of the nanoparticles. 
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charged surfactant (CTAB) at 5% w/v resulted in a polydispersed population of 
nanoparticles ranging from 50-800 nm (Figure 3-10C). Combining these two parameters 
(particles with 5% CTAB addition and a ratio of 1:1 chloroform:DMF) resulted in 
monodispersed nanoparticles ranging from 50-150 nm in diameter (Figure 3-10D). The 
size distribution of the nanoparticles based on ImageJ analysis of SEMs are included as 
insets for each set of particles 
Figure 3-10: Using the same polymer (PLGA 50:50, 17 kDa) and concentration (10% w/v) particles 
ranging in size from the micrometers (A) to nanometers (D) were fabricated. By increasing the amount 
of DMF (higher dielectric constant and surface tension) instead of chloroform, polydispersed 
microparticles (A) could be downsized to bimodal particles where one set was at approximately 1 µm 
and one at 100 nm (B). Alternatively, by adding a charged surfactant (higher dielectric constant and 
charge) polydispersed microparticles (A) could be downsized to polydispersed nanoparticles ranging in 
size from 50-800 nm. Combining both higher DMF content and charged species resulted in 
monodispersed nanoparticles in the 50-150 nm range. The insets in each image represent the zoomed in 
image of the particles (top) and the size distribution of the particles based on Image J analysis of SEM 
images (bottom).  
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 Once the fabrication of nanoparticles using EHD co-jetting was established, we 
were interested in determining whether the particles were still compartmentalized. Due to 
the small size of the nanoparticles, super resolution Structured Illumination Microscopy 
(SIM) was used to determine the bicompartmental nature of the particles. Nanoparticles 
containing red and green dyes in separate compartments were jetted using 5% w/v CTAB 
and a 97:3 ratio of chloroform: DMF. The particles were then imaged (Figure 3-11) via 
SIM imaging, which clearly confirms the compartmentalized nature of the nanoparticles.   
 In addition to fabricating monodispersed nanoparticles, the separation of a single 
polydispersed sample into uniformly sized fractions can be of interest, especially since it 
Figure 3-11: Super resolution Structured Illumination Microscopy (SIM) analysis of nanoparticles. 
Particles with a green dye in one compartment and a red dye in the second compartment were jetted 
using a 5% incorporation of CTAB and a 97:3 ratio of solvents chloroform:DMF. The insets on the 
right are individual particles zoomed out image on the left. 
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allows for the side-by-side testing of nanoparticles from the same batch (same material 
and physical characteristics) but with different size ranges. This fractionation can be 
achieved by using serial centrifugation (Figure 3-12A), where a polydispersed sample of 
particles (here the sample in 3-10C) is centrifuged at 9400 RCF (relative centrifugal 
force) for increasing times to pellet increasingly smaller particles. The size distribution of 
several fractions (1, 10, 20, and 30 minutes) are shown in Figure 3-12B and a SEM image 
of the 30 minute sample is shown in Figure 3-12C.  
 
 
 
 
 
 
 
 
 
 
 
Towards Multifunctional Nanoparticles 
 With the establishment of the fabrication and purification of nanoparticles into 
uniform size ranges, the use of these techniques in addition to those outlined in Chapter 2 
Figure 3-12: Separation of a polydispersed group of nanoparticles into monodispersed fractions using 
serial centrifugation. (A) Schematic displaying serial centrifugation. (B) Size distribution of different 
fractions (1, 10, 20, and 30 minutes) based on DLS measurements and (C) a representative image of 
uniform 50 nm particles from the 30 minute sample.  
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were explored for the fabrication of multifunctional nanoparticles. To begin with, the 
ability to functionalize the surface of nanoparticles with ligands and the density of such 
ligands on the surface was determined (Figure 3-13). This information can be of interest 
in determining the density of stealth and targeting molecules on the surface of 
nanoparticles, especially when multi-valency experiments with respect to the effect of the 
number of ligands on circulation or targeting is of interest. Nanoparticles with polymer 6 
were fabricated and purified into an approximately 100 nm fraction (Figure 3-13C). 
These alkyne-functionalized nanoparticles were then incubated with 0.01, 0.1, 1 mg of 
azide-PEG-FITC and the surface of these particles was functionalized with this molecule 
through copper catalyzed click chemistry (Figure 3-13A). The nanoparticles were then 
pelleted via centrifugation and the unreacted azide-PEG-FITC was removed and 
Figure 3-13: Functionalizing the surface of nanoparticles with azide-PEG-FITC to determine the ligand 
density per surface area. (A) Schematic displaying methods used. (B) Calibration curve of azide-PEG-
FITC at different concentrations using UV visible spectroscopy and (C) the size distribution of the 
nanoparticles as a function of concentration.  
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measured via UV visible spectroscopy based on a previously established calibration 
curve (Figure 3-13B).  
 Based on this information, the total amount attached to the nanoparticles and the 
total surface area of the nanoparticles could be calculated, where the amount of azide-
PEG-FITC attached is the total amount incubated subtracted by the amount removed at 
the end of the experiment and the total surface area of the nanoparticles can be calculated 
based on the known diameter and the concentration of nanoparticles at each given 
diameter. Together, this data was used to plot the ligand number per nm2 of the 
nanoparticles (Figure 3-14). As expected, the ligand number per surface area increases 
with increasing concentration used for the surface modification from 0.02-6.04 ligands 
per nm2. This data corresponds well with other reported data in the literature that range 
from 4.2-28.5 ligands per nm2 depending on the particles, chemistries, and techniques 
used.153, 154 Repeating the same experiments with particles with only one compartment 
Figure 3-14: Ligand density determination on the surface of nanoparticles. The ligand density per nm2 
is graphed based on the nanoparticle used (one or two active compartments) and the starting 
concentration of ligands incubated for the reaction.  
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containing the active ligand (alkyne), a distinct difference at the higher concentrations 
closer to the saturation point of the functional groups on the surface can be observed. 
This data further confirms the compartmentalization of the functional polymers and their 
surface ligands on the multicompartmental nanoparticles. 
 With the establishment of surface modifications on nanoparticles and an estimate 
of the PEG ligands on their surface, we were interested in using this information to 
functionalize the surface of nanoparticles for biodistribution studies in animals. 
Nanoparticles containing polymer 6 for surface functionalization with an eight-armed 
PEG and a phenol-containing polymer for radioactive labeling with I125 were fabricated. 
The base polymer used (50% w/w) was PLGA and each of the functional polymers were 
present at a 25% w/w in the nanoparticles. The route used for the functionalization of the 
nanoparticles, SEM images directly after fabrication, and their size distribution before 
and after PEG-ylation with an eight-arm azide-PEG molecule is shown in Figure 3-15. 
The size distribution of the particles after separation was at approximately 140 nm, and 
this size was increased to approximately 200 nm with the addition of the PEG molecules 
(40 kDa) to the surface.  
 Further functionalization of the nanoparticles with I125 and their biodistribution in 
mice were done in collaboration with Prof. Muzykantov’s group at the University of 
Pennsylvania based on previously published results.142 Briefly, the nanoparticles were 
incubated with I125 and iodobeads to attach the I125 to the phenol groups of the 
nanoparticles through the electrophilic aromatic substitution where the iodione is inserted 
in the ortho position to the hydroxyl group of the phenol molecule.142 The I125 substitution 
allows for the detection in animal models via gamma counters and I124 incorporation can  
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be used for the detection of beta emitters using PET (positron emission tomography) or 
SPECT (single photon emission computer tomography) imaging. After attachment, the 
nanoparticles are purified from unreacted material through multiple washes and 
centrifugations before inserting them into animals intra-orbitally. The animals (3 groups 
of 5 animals each) were sacrified at 1, 4, and 24 hour periods and their various organs 
were analyzed to determine the distribution of the nanoparticles within them as a function 
of the injected dose (ID) per mass of organ (g) (Figure 3-16). As a note, the animals were 
not perfused with a buffer before taking the measurements and each organ contained its 
respective blood supply. Not surprisingly, the majority of nanoparticles accumulate in the 
Figure 3-15: Functionalization of nanoparticles with star PEG and I125 for use in biodistribution studies. 
(A) Schematic outlining the steps taken to first surface functionalized the nanoparticles with star-PEG-
azide via copper catalyzed click chemistry and the subsequent radioactive labeling of the phenol groups. 
(B) DLS measurements of nanoparticles before and after PEG-ylation and (C) the as-fabricated 
nanoparticles with a size range of 60-150 nm. 
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liver and spleen, especially since these nanoparticles were not targeted to a specific site in 
the body. However, a not insignificant portion of the nanoparticles (approximately 4% 
ID/g) continued to circulate after one hour, which droped to 1.2% ID/g even after 24 
hours. This distribution compares well with published results of similar nanoparticles 
fabricated through the double emulsion technique where less than 1% ID/g of PEG-ylated 
nanoparticles were seen after 12 hours.155 
 
 
 
 
 
 
 
 
 
 
 
Fabrication of Hydrogel Nanoparticles 
 In addition to fabricating biodegradable nanoparticles using PLGA derived 
polymers, the possibility of producing biocompatible hydrogel nanoparticles was 
explored. Hydrogel nanoparticles have the benefit of being hydrophilic, pH responsive, 
flexible, and biocompatible given the materials used to synthesize them.156 Here, 
Figure 3-16: Biodistribution of the nanoparticles in mice. (A) Schematic of the particle fabrication 
method and intra-orbital injection into mice and (B) the biodistribution of the nanoparticles (% Injected 
Dose (ID) per gram of tissue) for individual organs. 
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nanoparticles composed of human serum albumin and NHS-PEG-NHS were fabricated. 
The NHS-PEG-NHS molecules acted as the cross-linker in the nanoparticles where the 
various albumin molecules were connected via their free amine-groups to each other. 
Albumin and PEG were chosen due to their biocompatibility and their low opsonization 
rates in the body.1 It was observed that uniform nanoparticles with an average diameter of 
125 nm could be fabricated in high yields through this process (Figure 3-17). This size 
increased to 300-400 nm in a buffered solution at pH 7.4 and an increased swelling in 
size to 600-700 nm could be achieved by reducing the pH of the solution to 5 (Figure 3-
17C). This could be of interest when fabricating nanoparticles for endosomal escape (pH 
of 4-6) or targeted release of therapeutics near tumor tissue or inflamed sites where the 
pH is significantly lower than the physiological range.147, 148 
 
Figure 3-17: Fabrication of hydrogel nanoparticles. (A) Schematic of nanoparticle fabrication from 
albumin and NHS-PEG-NHS via EHD jetting. (B) SEM images of uniform nanoparticles and (C) their 
size distribution in various pH buffers. 
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 One of the unique aspects of hydrogel nanoparticles is their tunability with respect 
to their size, swelling properties, and loading. Here their swelling properties as a function 
of increasing cross-linker concentration was explored. As displayed in Figure 3-18 an 
increase in the cross-linker density does not significantly affect the dry-state size of the 
nanoparticles (Figure 3-18 A-C SEMs and D size distributions), but has a significant 
affect on their size distribution in a buffered solution (Figure 3-18E). The size of the 
nanoparticles can be controlled by increasing their cross-linker density from 
approximately 400 nm to 180 nm. This can have important implications in terms of the 
release of payloads as well as their functionality within the body depending on their 
flexibility and mechanical properties.156 
 
Figure 3-18: Controlling the swelling properties of hydrogel nanoparticles. (A-C) SEM images of 
nanoparticles with increasing amounts of cross-linker density from 1-3X respectively. (D) The size 
distribution of the nanoparticles in their dry state based on SEM images and (E) their size distribution in 
pH 7.4 depending on their cross-linker density. 
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Fabrication of Janus Nanoparticles for Possible Self-Assembly Applications. 
 Thus far, while the fabrication of multicompartmental nanoparticles composed of 
a variety of different polymers has been established, the incorporation of dissimilar 
materials in each compartment has not extensively been explored. To this end, the 
fabrication of nanoparticles with two different polymers was attempted. The polymers 
used were polymethyl methacrylate (PMMA) and poly-tert-butyl methacrylate (PtBMA) 
where one is more hydrophilic than the other, respectively. Nanoparticles composed of 
such polymers in distinct compartments have the potential of being used as functional 
surfactants due to their self-assembly capabilities at water-oil or water-air interfaces. To 
begin nanoparticles with each polymer separately were fabricated to determine the 
conditions needed for each (Figure 3-19). It was discovered that a different solvent ratios 
Figure 3-19: Fabrication of Janus nanoparticles. (A-C) SEM images of as-fabricated nanoparticles of 
PMMA, PtBMA, and both polymers, respectively. (D) The size distribution, average diameter, and 
concentration of the fabricated nanoparticles. 
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of chloroform to DMF (7:3 vs. 8.5:1.5) was needed for the fabrication of PMMA versus 
PtBMA nanoparticles, respectively. The combination of these two separate formulations 
in a side-by-side jetting orientation resulted in the fabrication of Janus nanoparticles. The 
nanoparticles as fabricated can be seen in Figure 3-19 A-C with PMMA, PtBMA, and 
both polymers, respectively. The size distribution of the nanoparticles after centrifugation 
for 6 hours at 4000 RPM as well their concentration in high yields are noted. 
Additionally, the compartmentalization of the nanoparticles was determined using SIM 
imaging. Here, the Janus particles contained either a green or red dye in separate 
compartments and their bicompartmental nature can be seen in Figure 3-20.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-20: SIM imaging of Janus nanoparticles composed of PMMA and PtBMA polymers in 
separate compartments. 
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3.4 Summary 
 
 Throughout this chapter, control over various physical properties of a particle 
have been explored. Such properties as shape, roughness, porosity, charge, and size were 
imparted to the particles by controlling different variable in the EHD co-jetting 
fabrication process such as polymers used, solution characteristics, and external 
environmental conditions. A focus was placed on the fabrication and testing of 
nanoparticles with respect to controlling their as-fabricated size range, separation into 
specific size fractions for polydispersed samples, displaying their bicompartmental 
nature, determining their surface functionalization and ligand density, and their 
biodistribution in animal models. Additionally, the fabrication of uniform hydrogel 
nanoparticles and Janus nanoparticles with two different polymers in separate 
compartments were investigated. Together, this chapter establishes a set of 
methodologies that can be used to program the different physical properties of a particle 
system for a given application. 
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CHAPTER 4 
Fabrication of Particles with Complex Release of Therapeutics 
 The material in this chapter has been adapted with minor modifications from the 
following published article: 
(1) S. Rahmani, T.-H. Park, A. F. Dishman, J. Lahann, “Multimodal Delivery of 
Irinotecan from Microparticles with Two Distinct Compartments”, J. Control. 
Release, 2013, 172, 239-245. 
(2) S. Rahmani, S. Saha, A. Donini, J. Lahann, “Controlled Degradation and Release 
from Anisotropic Particles”, In preparation. 
(3) E. Sokolovskaya, S. Rahmani, A. C Misra, S. Bräse, J. Lahann, “Dual Stimuli 
Responsive Microparticles”, Submitted, 2014. 
 
 
4.1 Motivation and Background 
 
 One of the many challenges in designing a multifunctional carrier for the delivery 
of therapeutics is their ability to encapsulate therapeutics and deliver them with the 
desired pharmacokinetics. The challenge here is not necessarily the simple release of the 
therapeutic, but the release at constant and pre-determined rates that can reach therapeutic 
levels. Another concern is that as delivery carriers become more efficient in increasing 
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local therapeutic concentrations, the risks associated with the unsolved issue of cellular 
drug resistance can arguably be elevated.157, 158 A promising approach to avoid drug 
resistance may be the combined use of multiple therapeutics. This delivery will require 
complex release profiles to accommodate the differences in the pharmacological 
windows of the respective drugs.159 Thus, a new generation of drug carriers is needed that 
can release (i) two or more drugs; (ii) with fully decoupled release profiles. If chosen 
carefully, such carrier systems would also benefit from possible synergistic effects of the 
drugs that can further enhance the therapeutic efficacy of the combined delivery.160, 161 
Several researchers have proposed possible strategies for the incorporation of complex 
release profiles in carrier systems, some of which include the use of stimuli responsive 
material for on-demand and complex release kinetics.19, 148, 162-164 Responsive material 
can be highly sensitive to external stimuli such as pH, temperature, light, and oxidative 
stress.164 The structure and degradation of particles composed of stimuli responsive 
material can then be controlled, and on-demand pharmacokinetics of the encapsulated 
therapeutics can be achieved.148, 164, 165 Beyond simple prolongation of the release,17 these 
drug carrier systems can be tailored to the therapeutic window associated with a specific 
disease.162, 163 
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4.2 Experimental Methods 
 
4.2.1 Materials 
 Dextran, chloroform, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 
pyridinium p-toluenesulfonate, 2-methoxypropane triethylamine, acetic acid, sodium 
acetate, poly[tris(2,5-bis(hexyloxy)-1,4-phenylenevinylene)-alt-(1,3-phenylenevinylene) 
(PTDPV), poly[(m-phenylenevinylene)-alt-(2,5-dihexyloxy-p-phenylenevinylene)] 
(MEHPV), Triethyl amine, bromoacetyl bromide, dimethyl amino pyridine, Benzyl 
alcohol, l-lactide, tin (II) ethyl hexanoate, anhydrous toluene, Palladium 10% wt. on 
activated carbon, anhydrous tetrahydrofuran (THF), Allyl glycidyl ether (AGE), 
naphthalene, potassium, 2,2α-azobis(2-methylpropionitrile) (AIBN), poly(lactic-co-
glycolic acid) (PLGA, 85:15, Mw= 50000 – 75000 g/mol), manganese chloride, 
tetramethylrhodamine-5-(and 6)-isothiocyanate (TRITC, red emission dye), phosphate 
buffered saline (PBS), bovine serum albumin (BSA), tris-buffered saline (TBS), and 
tween 20 were used as purchased from Sigma Aldrich, USA. Thioglycolic acid, o-
nitrobenzyl alcohol, hydrogen peroxide solution (30%), calcium hydride, sodium, 
anhydrous sodium sulfate, concentrated sulfuric acid, and acetic acid were purchased 
from Merck KGAA. Polylactide-co-glycolide (PLGA) with a ratio of 50:50 lactide to 
glycolide and a molecular weight of 44 kDa was purchased from Lactel Corporation. 
Irinotecan was purchased from Ontario Chemicals. 2-Methoxyethanol and O-benzyl-L-
serine was purchased from Alfa Aesar.  Sodium bicarbonate, dichloromethane, methanol, 
toluene, acetonitrile, N,N-dimethylacetamide (DMAc) were purchased from BDH 
Prolabo.Sulfuric acid, acetonitrile, sodium nitrite, dichloromethane, sodium carbonate, 
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Tissue-Tek O.C.T, and acetone was purchased from Fisher Scientific. Diethyl ether was 
purchased from Acros Organics. Hydrogen was provided by Cryogenic Gases. Prolong 
Gold Antifade Reagent was purchased from Life Technologies.  
 
 
4.2.2 Fabrication & Testing of Drug Loaded Particles with a Rapidly Degrading 
Polymer 
 
 The synthesis of polymer 2 (3-Hydroxyl PLGA) was done Dr. Sampa Saha and 
the details are outlined in Appendix A. The solutions used for jetting particles were made 
with a 97:03 ratio of chloroform: DMF and a polymer concentration of 10% w/v.  
Depending on the particle set, a certain percentage (10, 50, and 100%) of the polymer 
used in the jetting solution on one side was polymer 2, while the rest was PLGA.  In all 
cases, the other compartment was composed of neat PLGA.  The flow rate used was 0.4 
mL/hr. For degradation studies, particles were incubated in PBS at 37 oC and at 
predetermined intervals samples were taken, washed, and imaged via SEM to determine 
their degree of degradation. 
 For release studies, particles with 2% drug loading per compartment were 
fabricated using the same procedure as described above.  The 2% loading was determined 
based on conventional methods: 
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The pre-determined amount of drug was mixed into the jetting solutions along with the 
polymers prior to the jetting. To determine the particles’ release kinetics, the jetted 
particles were collected into four 20 mg samples, suspended in five mL of PBS and 1% 
v/v Tween 20 buffer, and placed in a 100-kDa dialysis membrane.  The membrane was 
inserted into a Falcon tube containing 35 mL of the same buffer and gently shaken at 37 
oC. At predetermined intervals, the tubes were removed from the incubator, the 
membranes were inserted in new tubes with 35 mL of fresh buffer, and replaced back in 
the incubator.  The drug containing buffers in the Falcon tubes were then measured via a 
UV Visual spectroscopy machine at 367 nm to determine the amount of drug released 
based on a calibration curve done at the same wavelength previously.  The amount of the 
drug released at each point was added to the previous ones to determine the total amount 
released at each stage, while taking into account released drug remaining in the 
membranes.  The one-hundred encapsulation percentage was determined by dissolving a 
known amount of particles in DMF and measuring the final encapsulation based on a 
corresponding calibration curve done in DMF.  The release was plotted as a function of 
the total cumulative release versus time. 
 
 
4.2.3 Fabrication & Testing of Drug Loaded Particles with a pH Responsive 
Polymer 
 
 The details regarding the fabrication of pH responsive particles using polymer 8 
and their degradation study are outlined in section 3.2.3. Drug loaded microparticles were 
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fabricated using the same procedure. Here, the drug (irinotecan) was mixed in the jetting 
solution containing polymer 8 prior to the jetting. The encapsulation was done as a drug-
to-polymer ratio (5:100, 10:100, 25:100, and 50:100). These ratios correspond to 2.4, 4.8, 
11.1, and 20% drug loading of the particles, respectively, taking into account both 
compartments. The drug loading was calculated as the drug mass divided by the 
combined mass of the polymer and drug, as shown in section 4.2.3.     
For release studies, 20 mg of the microparticles were dispersed in 5 ml at pH 7.4. 
The solutions were then placed in dialysis membrane tubing before inserting them into 
containers filled with 35 ml of the same buffer. The dialysis membrane separated the 
internal solution and limited the diffusion of material at a cut-off range of 100 kDa, 
thereby allowing the diffusion of the drug, but not the microparticles, out of the 
membrane. The samples were incubated at 37 oC. Eight samples were prepared for each 
of the drug-to-polymer ratios. At predetermined intervals, the membranes were switched 
to a new container with fresh buffer, and the buffer containing the released drugs was 
measured using a UV spectrometer to determine the amount of drug released according to 
a calibration curve. The amount released at each stage was added to the previous amounts 
to determine the total amount of drug released at each fixed point. At 24 hours, four out 
of eight samples for each ratio were centrifuged down and the buffer was fully replaced 
with a pH 5 buffer. The samples were placed back in the incubator and the release was 
continued with 4 samples at pH 5 and 4 samples at pH 7.4.  
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4.2.4 Fabrication of Particles with a Dual Responsive Polymer 
 
 The synthesis of the dual responsive polymer was graciously done by Dr. 
Ekaterina Sokolovskaya and are fully described in Appendix C. Particles were fabricated 
by the EHD co-jetting process. Two different polymer solutions were prepared: one 
solution contained 15 w/v% PLGA (50:50, 40 kDa), another 15 w/v% 1:1 w/w mixture of 
PLGA and polymer 10 or polymer 11. A mixture of chloroform and DMF (97:3 v/v) was 
used as the solvent. For confocal Raman microscopy analysis of PLGA/polymer 11 
microspheres, the ratio of PLGA and polymer 11 in the second solution was changed to 
3:1 w/w correspondingly. 
 Microfibers were generated using a setup similar to that used for the generation of 
microspheres except the concentration of polymers in both solutions was changed to the 
following: one solution contained 30 w/v% PLGA, another solution was prepared by 
mixing 30 w/v% of PLGA with 22.5 w/v% of polymer 10 or polymer 11 (75% by weight 
of PLGA). For both compartments PLGA (85:15, 55 – 75 kDa) was used. The flow rate 
was set to 0.05 mL/h and the microfibers were collected at a distance of 7 cm using a 
rotary collector and embedded in a freezing medium (OCT). For confocal Raman 
microscopy analysis of PLGA/polymer 9 microfibers the concentration of polymer 11 in 
the second solution was decreased to 15 w/v% (50% by weight of PLGA).  
 For photo-degradation, PLGA/polymer 10 and PLGA/polymer 11 microspheres 
or microfibers were exposed to 365 nm light on the collecting substrate for 30 min, 
followed by incubation in a buffer composed of TBS and 0.01% Tween 20 for 1 h while 
rotating. Next, the particles were washed 5 times with DI-water, analyzed by SEM. As a 
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control experiment, incubation of non-irradiated particles in the same conditions was 
performed.  
 The particles were collected from the metal substrate using a buffer composed of 
PBS, 0.01% Tween 20, and 10% BSA. Once collected, the particles were filtered through 
a 40 µm filter to remove large aggregates and then were counted using a cell counter to 
determine the final concentration in the solution. Raw264.7 cells were seeded in a 12-
well plate with cover glass slides at a concentration of ~80000 cells/well. The following 
day, the cells were incubated with particles at different concentrations (in fresh media) 
for four hours. After the incubation, the cells were washed with PBS and fixed in 4% 
paraformaldehyde. Following fixation, the cells were washed with PBS once more and 
stained with far-red phalloidin, as per the protocol provided by Invitrogen. The coverslip 
samples were then mounted on glass slides using ProLong Gold Antifade Reagent with 
DAPI and imaged through CLSM. The scanned images were then analyzed to determine 
particle uptake per cell at the different particle concentrations. 	  	  
Results and Discussion 
 
Particles with Controlled Release of Therapeutics: 
 The precise control over the release rate of therapeutics from particles is 
responsible for determining whether a carrier system is capable of reaching therapeutic 
indices in the body. Here, we were interested in working with rapidly degrading polymers 
as a means for fabricating particles with controlled therapeutic release. One of the 
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synthesized polymers in Chapter 2, polymer 2, contains free hydroxyl groups on its 
backbone. In the previous chapters, the use of this polymer for surface functionalizing 
particles via EDC/Sulfo-NHS chemistry and as a method of imparting surface charge to 
particles were investigated (Chapters 2 and 3 respectively). Due to these hydroxyl groups, 
the polymer is also expected to degrade at a faster rate than neat PLGA polymers with 
similar molecular weights. To validate this hypothesis, particles with different 
percentages of polymer 2 in one compartment (0, 10, 50, and 100% w/w) were fabricated. 
Upon incubation of the particles in physiological conditions and their imaging with SEM, 
the degradation of the microparticles dependent on the amount of polymer 2 incorporated 
was observed (Figure 4-1). The particles containing 100% polymer 2 in one 
compartment degraded rapidly and by day one only the hemisphere containing PLGA 
remained. Further degradation starting at the interface of the two compartments and 
Figure 4-1: Degradation of microparticles with various percentages of polymer 2 in one compartment. 
Each row represents a different particle composition, while the x-axis represents the time points used. 
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through the bulk of the second compartment yielded hollow half spheres by the second 
day. This rapid degradation of the PLGA compartment is most likely due to the lower pH 
environment induced by the degradation of polymer 2. The particles with 50% of this 
polymer degraded at a slower rate, with pores seen selectively in one compartment by 
day 2, followed by the degradation of one compartment by day 4. The particles 
containing only 10% of polymer 2 in one compartment degraded at a much slower rate 
with pores seen only after 11 days.  
 Based on these studies, the controlled degradation of a selective compartment was 
established. Next, we employed these particles to establish controlled release of a cancer 
therapeutic (Irinotecan). The same particles used in Figure 4-1 with a 2% w/w loading of 
irinotecan were used for the release studies (Figure 4-2). A control with only PLGA on 
both sides and loaded with irinotecan was used as a reference. A similar trend to the 
degradation can be observed here: the higher the ratio of polymer 2, the faster the 
Figure 4-2: Release of irinotecan from microparticles containing various percentages (0, 10, 50, 100%) 
of polymer 2. The inset shows the first 48 hours of the release in detail. 
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degradation of the particles and the release of their therapeutic loading. By 15 days, the 
control particles composed of PLGA had a constant release of irinotecan to ~75%. The 
incorporation of polymer 2 at 10% w/w increased this rate to 95% by 15 days. However, 
the incorporation of this polymer at 50 and 100% resulted in a rapid release of irinotecan 
where approximately 100% of the encapsulated therapeutic was released by 10 days. The 
inset in Figure 4-3 highlights the first 48 hours of the study, where the precise control 
over the release kinetics of the therapeutic is clearly demonstrated. Such formulations 
could potentially be used for the fabrication of particles with controlled release kinetics.  
	  
Particles with pH Responsive Release of Therapeutics:  
 The synthesis of polymer 8 (Acetal Dextran) was done by Dr. Tae-Hong Park and 
the details are outlined in detail in section 3.2.3. The porosity and degradation of the 
compartmentalized particles with polymer 8 in one compartment is also discussed in 
detail in section 3.3. Here, we were interested in exploring the pH responsive capabilities 
of this system to fabricate responsive release of therapeutics from the particles. To this 
end, microparticles encapsulating different amounts of irinotecan in the compartment 
containing polymer 8 were fabricated. Microparticles with a range of different drug-to-
polymer ratios (5:100 to 50:100, drug: polymer ratio, wt./wt.) could be fabricated using 
the same polymer formulation and processing parameters. Even for extremely high 
loading ratios of up to 50:100, microparticles were obtained that maintained similar size 
and shapes to unloaded microparticles. Next, four different microparticle sets were 
fabricated with drug-to-polymer ratios of 5:100, 10:100, 25:100, and 50:100. We 
hypothesized that at physiological pH, there would be a relatively slow release of the 
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drug from our microparticles, while in acidic pH, there would be a rapid release of the 
majority of the drug. Finally, the rapid release at pH 5 was anticipated to follow a similar 
pattern (time and rate) as that of the dextran release (Figure 3-5).   
 To test this hypothesis, release studies were conducted with the bicompartmental 
microparticles. Two sets of samples were used for each drug-to-polymer ratio. For the 
first 24 hours both sets were incubated at pH 7.4 to determine if the release between the 
sets were consistent, then one set was switched to pH 5 while the other was kept at pH 
7.4 as a control. As predicted, the two sets were consistent with a slow release of 
irinotecan during the initial 24-hour period, after which point the samples were switched 
to pH 5 and underwent rapid release. Meanwhile, the reference samples, stored at pH 7.4, 
continued to display a very slow release of the therapeutic (Figure 4-3B). The detectable, 
albeit small, burst and the continuous release thereafter match those of the dextran release 
at the same pH (Figure 3-5). We note that the rapid release of irinotecan at pH 5 is 
consistent with our previous results. While the majority of the compartment was 
composed of polymer 8, there is still a significant PLGA component in this compartment 
(25%), which, does not completely degrade within the 10-hour period and retains some of 
the irinotecan. Thus, irinotecan can be released in two stages: a rapid stage through the 
release of polymer 8 within a 10-hour period and a slower release phase as the PLGA 
component degrades.   
 In addition to establishing that pH-triggered, on-demand release of therapeutics 
can be achieved with bicompartmental microparticles, we were also able to demonstrate 
that the rate and amount of release can be tuned, depending on the amount of the 
therapeutic encapsulated in the microparticles. As demonstrated in Figure 4-3, as the 
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drug-to-polymer ratio was increased (Figure 4-3D to Figure 4-3A), the amount of drug 
and the rate of release were also increased. This is in agreement with previously 
published results166 confirming that at higher drug concentrations, the release of the 
therapeutic is faster due to percolation effects.167, 168 This is particularly evident in the 
case of the microparticles with a drug-to-polymer ratio of 50:100 (Figure 4-3A) where 
the release of the drug is very fast, irrespective of the pH of the release environment.   
  
Figure 4-3: Release of irinotecan from bicompartmental microparticles.  A.-D.) Release profiles from 
microparticles with drug-to-polymer ratios of 50:100 (A.), 25:100 (B.), 10:100 (C.), and 5:100 (D.).  
The solid lines are of the release in pH 5 and the dotted lines are the release in pH 7.4.  
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 Another potentially useful characteristic of bicompartmental carriers containing 
polymer 8 is their ability to localize high drug content in one compartment without spill 
over into the second one.  This is a feature that was not possible in microparticles 
containing PLGA. Figure 4-4 displays the selective encapsulation of the drug, irinotecan, 
at high drug-to-polymer concentrations (25:100) in the same compartment containing 
polymer 8 (Figure 4-4A). For comparison, the same drug at the same concentrations was 
also loaded in bicompartmental microparticles comprised of PLGA in both 
compartments. For microparticles without polymer 8, diffusion of the drug between the 
two PLGA compartments was observed (Figure 4-4B). In contrast to the microparticles 
Figure 4-4: Selective encapsulation of irinotecan in microparticles.  A.) In polymer 8 containing 
microparticles, irinotecan (autofluorescing in blue channel) is compartmentalized in one compartment, 
as the two dyes do not mix in the overlay image (A3.).  B.) In the PLGA containing microparticles, the 
encapsulated irinotecan is not compartmentalized, as in the overlapped image, B3.), the blue dye is in 
both compartments.  The structure of the drug, irinotecan, and the polymers, polymer 8 and PLGA, are 
displayed in C1-3. 
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containing polymer 8, irinotecan is distributed throughout the entire microparticle as 
indicated by the overlay of the blue fluorescence from irinotecan (Figure 4-4A3 and 4-
4B3) and green fluorescence used to label the irinotecan-free compartment (Figure 4-4A2 
and 4-4B2).  
	  
Selective Degradation of Particles Using a Dual Responsive Polymer:  
 Materials capable of changing their properties in a controlled and reversible 
manner in response to changes in their environment or a specific trigger, such as light, are 
defined as “smart” materials.169 Stimuli-responsive materials have been designed in 
various forms including switchable surfaces,169-172 responsive hydrogels,173 or anisotropic 
particles.73, 169, 174 Compared to many known triggers, light switching can be performed in 
milder conditions and in a more specific manner due to control over light intensity and 
wavelength.175 A wide range of photoresponsive systems has been developed thus far.173, 
176, 177 For example, azobenzene derivatives and spiropyrans were successfully used for 
the fabrication of photoresponsive surfaces.172 In the field of drug delivery, 
photocleavable protecting groups are commonly used to switch the solubility of carrier 
polymers. A variety of photolabile protecting groups are available for different 
functionalities.178, 179 In particular, o-nitrobenzyl (NB) groups have found a range of 
different applications.180 Originally designed for use in organic synthesis,181 these groups 
were successfully applied to biochemistry.42 When incorporated into a copolymer, the 
photocleavage of the NB groups takes place readily upon illumination with UV light, 
releasing alcohol or acid and a nitroso derivative.180 
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 Besides light, potential triggers for stimuli responsive material include changes in 
temperature, pH, salt content, presence of specific molecules, and electrical or magnetic 
fields.162, 176, 177 To date, there exist only a very few examples of stimuli-responsive 
materials triggered by changes in the oxidative environment of a tissue, as it is commonly 
observed in inflammatory tissues.162 A change in the redox environment of a cell due to 
oxidative stress is an important indicator of many diseases including cancer,182 
atherosclerosis,183 neurodegenerative diseases such as Parkinson’s disease and 
Alzheimer’s disease,184 or heart failure.185  
 Oxidative stress may originate from the overproduction of reactive oxygen and 
nitrogen species. The latter are generated as byproducts of aerobic metabolic cell 
processes involving reduction of oxygen to superoxide anions followed by formation of 
hydrogen peroxide, hydroxyl radicals, hypochlorite, peroxynitrite, and other 
molecules.186, 187 At high dosages, oxidants can cause significant damage to proteins, 
lipids, and DNA, and finally lead to cell death.  Therefore, the presence of oxidants can 
be used as a marker for inflamed tissues and can activate a specific action of a 
biomaterial, such as drug release.188 Here, we were interested in the synthesis of a new 
multifunctional poly(ethylene glycol) (PEG)-based polymer particle that contains both 
redox-responsive thioether moieties and light-sensitive NB groups. Specifically, this 
design takes advantage of the co-operative effects of hydrogen peroxide reactive moieties 
(endogenous stimulus) and photoresponsive groups (exogenous stimulus).  
 We used electrohydrodynamic co-jetting to formulate anisotropic microparticles 
containing a dual-stimuli responsive polymer in one compartment. Oxidation of the 
thioether into sulfoxide groups under conditions of oxidative stress (endogenous 
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stimulus) and photocleavage of NB groups (exogenous stimulus) can then act 
cooperatively to increase the polymer solubility in water and lead to the rapid resorption 
of one compartment in these microparticles. If the particles are placed in an oxidative 
environment in the absence of UV light, no resorption will occur. The same is true for a 
particle that is exposed to light in the absence of the oxidative trigger (Figure 4-5). 
 We chose PEG as the main chain polymer, because PEG is known to have 
outstanding properties such as biocompatibility, hydrophilicity, protein resistance, and 
non-toxicity, which are particularly important for biomedical applications and have 
Figure 4-5: A) Polymerization of AGE and synthesis of multifunctional o-nitrobenzyl PEGs. B) 
Schematic representation of bicompartmental particles having the dual stimuli responsive polymer in 
one compartment (blue). The polymer contains NB groups, which are cleaved upon exposure to UV 
light releasing carboxylic acid groups (I) and thioether moieties, which undergo oxidation into sulfoxide 
groups upon hydrogen peroxide action (II). Only upon action of both light and oxidant does the polymer 
become completely water soluble due to the conversion into the corresponding polyacid with sulfoxide 
moieties leading to the degradation of the corresponding compartment of the particle (III). 
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already made PEG one of the most attractive polymers in biomaterial synthesis.189-191 
Moreover, the hydrophilicity of the PEG backbone contributes to the solubility of the 
polymer after combined exposure to endogenous and exogenous stimuli. Typically, PEG 
polymers are functionalized via their end groups, which limit the number of functional 
groups per PEG chain. This disadvantage can be overcome by the synthesis of 
multifunctional derivatives via anionic ring-opening polymerization of functional 
epoxides and subsequent post-polymerization modifications.192, 193 Thus, we first 
prepared poly(allyl glycidyl ether) (PAGE) as a starting polymer for the synthesis of the 
stimuli responsive polymer. Subsequently, polymer-analogue modification via thiol-ene 
“click” reaction yielded the polyether 10.  
 Polymer  was synthesized by anionic ring-opening polymerization of allyl 
glycidyl ether using 2-methoxy ethanol and potassium naphthalenide as the initiating 
system. The crude polymer was purified chromatographically over silica gel (Figure 4-5). 
The synthesis of the target PEG-based polymer containing both thioether and NB 
moieties was performed by post-polymerization modification of poly(allyl glycidyl ether) 
via thiol-ene reaction with a thiol bearing NB protected acid groups (Figure 4-5A). This 
method allowed the introduction of both stimuli reactive moieties in a single modification 
step. The thiol 2 NB bearing protected carboxylic acid group was then synthesized by 
esterification of thioglycolic acid with o-nitrobenzyl alcohol.  Reaction of polymer 9 with 
thiol 2 was performed in the presence of Azobisisobutyronitrile (AIBN) using an excess 
of thiol to avoid undesired crosslinking reactions. Complete conversion of allyl moieties 
was confirmed by 1H NMR spectrometry (Appendix C). The resulting polymer 10 was 
further purified chromatographically over silica gel. 
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 The final product, polymer 10, has the potential to function as a sensory material: 
Under conditions of oxidative stress, conversion of the thioether groups into sulfoxide 
groups will take place generating a substantially more polar polymer with enhanced 
resorbability in aqueous media. To compare the hydrophilic properties of polymer 10 and 
its sulfoxide analogue, the oxidation of polymer 10 with hydrogen peroxide into the 
corresponding polymer 11 was performed (Figure 4-5). To ensure that oxidation of 
thioether moieties proceeded just until the formation of sulfoxide groups and to avoid 
generation of sulfone groups in the polymer product, the oxidation reaction was allowed 
to proceed at 0 °C. Oxidation to the sulfone is highly undesirable, not only because of the 
difference in solubility of sulfoxides and sulfones, but also because of the low stability of 
sulfones, which can undergo degradation upon irradiation.187 However, detailed 
characterization of polymer 11 with 1H NMR and IR spectroscopy revealed no presence 
of sulfone groups (Appendix C). Moreover, the complete oxidation of the thioether 
groups was confirmed by the disappearance of a signal at 3.28 ppm in the NMR spectrum 
corresponding to the sulfur neighboring methylene protons (d') and the appearance of a 
new signal at 3.81 ppm from the corresponding protons (d'') in polymer 11 (Appendix C). 
This was also confirmed by IR spectroscopy, which revealed the appearance of a 
characteristic band at 1010 cm-1 corresponding to the (S=O) stretching bands in 
sulfoxides (Appendix C). GPC analysis indicated only a minor shift of the elution band of 
polymer 11 towards shorter elution times. We concluded that this shift is too small to be 
indicative of appreciable levels of degradation of polymer 10 during oxidation (Appendix 
C). Since the in vivo concentration of hydrogen peroxide under the conditions of 
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oxidative stress is relatively low,189 we expect the in vivo oxidation of polysulfides to 
predominantly result in sulfoxides, not sulfones. 
 Due to the combined redox-responsiveness and photoreactivity of the polymer, 
cleavage of the NB protecting groups of polymer 11 will result in the formation of the 
more polar polymer 12 (Figure 4-6). To validate this aspect systematically, the 
deprotection of polymer 11 was monitored by 1H NMR spectrometry in DMSO-d6 
solution through various exposures to UV light with a maximum wavelength of 312 nm. 
Disappearance of signals corresponding to aromatic (e–h) and benzylic (d) protons of the 
NB groups explicitly confirmed the cleavage of NB esters (Figure 4-7).  
 
 
 
Figure 4-6: Photocleavage of NB protecting groups in polymer 11 resulting in the formation of the 
corresponding polyacid 12 (A). Dependence of polymer 11 deprotection degree on the time of 
irradiation with 312 nm light (B). Deprotection degree was calculated based on 1H NMR spectra. 
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 On the other hand, methylene protons (a–c) were still present in the NMR 
spectrum showing the expected shifts (a'–c') after light exposure of the polymer. This 
aspect provides further evidence that degradation of the polymer can be ruled out (Figure 
4-7). Dependence of the deprotection degree of the polymer on UV exposure time is 
displayed in Figure 4-6. A somewhat longer than expected exposure period was needed 
for complete cleavage of NB groups, which was attributed to the used solvent (DMSO) 
and high concentration of the polymer (5 mg/ml). However, these conditions were 
necessary for proper detection and assignment of signals in the NMR spectra. To identify 
the optimum UV exposure time in bulk, polymer 11 was spin coated on gold wafers and 
exposed to light at a wavelength of 365 nm for different periods of time. Cleavage of the 
NB groups was then monitored by IR spectroscopy (Figure 4-8). The deprotection of NB 
groups was directly correlated to the disappearance of the characteristic nitro bands at  
Figure 4-7: UV induced cleavage of NB protecting groups in polymer 11 (A) and comparative 1H-
NMR spectra of polymer 11 before (B) and after (C) 4 h of irradiation with 312 nm light. Solvent 
DMSO-d6. 
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1530 and 1346 cm-1, as well as the shift of carbonyl band from 1742 to 1729 cm-1. 
Complete cleavage of NB protection was finally detected after light exposure for 30 min. 
 Anisotropic bicompartmental microspheres made of poly(lactic-co-glycolic acid) 
(PLGA) and containing the stimuli-responsive polymer 11 in one compartment only were 
prepared by EHD co-jetting (Figure 4-9).64 For bicompartmental particles, one jetting 
solution contained PLGA only, while the second solution contained PLGA/Polymer 11 
mixtures at a ratio of 1:1 (w/w). Both jetting solutions were loaded with fluorescent dyes, 
which allowed for confirmation of the bicompartmental structure of the microspheres via 
confocal laser scanning microscopy (CLSM) (Figure 4-9B). The spherical shape of the 
particles was confirmed by SEM (Figure 4-8C).Furthermore, the selective localization of 
polymer 11 in one compartment only was verified by confocal Raman microscopy 
Figure 4-8: Comparative IR spectra of polymer 11 before (control) and after different times of 
irradiation with 365 nm light. Polymer was spin coated on the gold wafers. 
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(Figure 4-9D-E). The characteristic signal of the nitro group at 1348 cm-1 was used as the 
reference band for assessing the spatial distribution of polymer 11 within the particle. 
Confocal Raman microscopy revealed the selective location of polymer 11 in only one 
hemisphere of the microsphere as indicated by the red signal. For comparison, the PLGA 
polymer is indicated by the blue color.  
 For comparison, bicompartmental particles with PLGA and polymer 10 were also 
prepared by EHD co-jetting and were characterized by SEM and CLSM. Based on the 
combined analysis of these results, both microspheres were found to be bicompartmental 
Figure 4-9: A) Schematic representation of the bicompartamental microparticles containing polymer 11 
localized in one compartment; B) CLSM image of the particles, where green and blue dyes indicate 
PLGA and polymer 11, respectively; C) SEM image of the particles, D) Confocal Raman microscopy 
spectra of the bicompartmental PLGA/polymer 11 microspheres; and E) 2D reconstruction of the 
Confocal Raman spectra, confirming the selective localization of polymer 11 (red) in one compartment 
(the ratio PLGA:polymer 11 in one compartment was 3:1). 
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and structurally identical. Next, the resorbability of PLGA/polymer 10 and 
PLGA/polymer 11 particles upon UV-irradiation was evaluated. For this purpose, dry 
particles were exposed to 365 nm light and washed with a Tris Buffered Saline (TBS) for 
30 minutes before imaging with a SEM. The SEM images of particles with and without 
UV exposure are shown in Figure 4-10B-E.  
 Without UV exposure, no resorption was detected for either PLGA/polymer 10 or 
PLGA/polymer 11 particles (Figure 4-10B and C). After exposure to markers of 
oxidative stress, the thioether moieties of polymer 10 underwent oxidation into sulfoxide 
groups, which make polymer 11 more hydrophilic than polymer 10. However, due to the 
Figure 4-10: Deprotection of polymers 10 and 11, respectively, into the corresponding polyacids upon 
exposure to light at 365 nm (A). SEM images of bicompartmental microparticles without light exposure 
(PLGA/polymer 10 (B)) and PLGA/polymer 11 (C)) and after 30 min light exposure (PLGA/polymer 
10 (D) and PLGA/polymer 11 (E)). 
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presence of the hydrophobic NB groups in both polymers, the resorbability of both 
polymers was still negligible. Similarly, particles comprised of PLGA/polymer 10 
showed no signs of resorption, even after exposure to UV light (Figure 4-10D). Even 
though photocleavage of NB protection in polymer 10 yielded the corresponding 
polyacid (Figure 4-10A), the absence of sulfoxide moieties was sufficient to prevent 
resorption of the deprotected polymer 10 (Figure 4-10D). In contrast, incubation of UV-
treated PLGA/polymer 11 particles led to fast resorption of polymer 11 (Figure 4-10E). 
Taken together, the results confirmed that only simultaneous exposure to both stimuli, 
light and markers of oxidative stress, allowed for the rapid resorption of polymer 10, 
whereas each stimulus on its own did not have sufficient effects to induce polymer 
resorption (Figure 4-10C-D). This suggests that PLGA/polymer 10 particles are a 
promising multi-stimuli responsive system by the dual actions of oxidants and UV 
exposure. 
 To further prove that the particles containing of polymer 3 and PLGA, and not 
just the polymer 11 containing particles that are pre-exposed to oxidative stress, are 
responsive to two stimuli, particles with polymer 10 were fabricated and their 
resorbability was examined by combined exposure to oxidative stress and UV light. As 
displayed in Figure 4-11, the particles were first exposed to hydrogen peroxide, which 
resulted in the more hydrophilic polymer 4. The particles were then exposed to UV light 
at 365 nm for 30 minutes, then washed and analyzed with SEM. The results clearly 
demonstrate that degradation of one hemisphere was achieved.  
	   106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11: Degradation of one compartment through oxidation and UV-illumination of 
bicompartmental microparticles. Here, microparticles composed of PLGA in one compartment (blue) 
and polymer 10 and PLGA in the second compartment (green) were incubated in 30% v/v hydrogen 
peroxide for 1 hour, followed by UV illumination at 365 nm for 30 min.  Similar to the treatment of the 
neat polymer, the hydrogen peroxide oxidizes the polymer 10 polymer to polymer 11, which is then 
water soluble upon UV illumination and the cleavage of the nitrobenzyl group. Upon oxidative and UV 
treatment, the particles were washed with DI water several times before imaging with a SEM to 
visualize the degradation of the particles. 
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3.4 Summary 
 
 In this chapter the incorporation of functional polymers in microparticles for 
controlled and stimuli-responsive selective degradation of particles and the release of 
their payloads is investigated. Particles containing polymer 2, a rapidly degrading 
polymer, were used to establish controlled release systems with release rates of 
therapeutics ranging from 2-3 days to over 15 days. We have also demonstrated the 
fabrication of environmentally responsive anisotropic microparticles containing polymer 
8 and characterized their pH responsive release of therapeutics. Additionally, the use of a 
novel dual stimuli responsive PEG-based polymer (11), where the co-operative action of 
both markers of oxidative stress and UV light induced rapid resorption of the polymer 
under physiological conditions, was explored. Here, the exogenous stimulus (UV light) 
acted as an on-switch, after which the particles became susceptive to the second, 
endogenous stimulus, a marker of oxidative stress. The resorbability of bicompartmental 
microparticles containing the dual-stimuli responsive polymer after exposure to UV light 
and oxidative stress was confirmed. Particles fabricated from these polymers, with their 
precisely controlled degradation of select compartments, can potentially be used to 
establish responsive nanoparticles with distinct release of multiple factors. 
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CHAPTER 5 
Design of Particles for Cochlear Drug Delivery 
 The material in this chapter has been adapted with minor modifications from the 
following articles: 
(1) S. Rahmani, A. M. Ross, T. H. Park, A. F. Dishman, H. Durmaz, D. Prieskorn, R. 
Altschuler, J. Lahann, “Multifunctional Microparticles for Cochlear Drug 
Delivery”, In preparation. 
(2) A. M. Ross, S. Rahmani, D. Prieskorn, N. Wys, A. F. Dishman, C. Martin, J. 
Lahann, A. Altschuler, “Persistence, Distribution, and Impact of Distinctly 
Segmented Microparticles on Cochlear Health Following In Vivo Infusion”, In 
preparation.  
 
 
5.1 Motivation and Background 
 
 Hearing is an integral part of an individual’s life and any degree of hearing loss 
and/or deafness can bring about life-altering changes.  In the US alone, over 36 million 
people, or 17% of the population, have been diagnosed with some level of hearing loss.194 
In fact, deafness is the number one disability in our nation.  Based on recent census 
information, one in three people over the age of 65 and half of those over the age of 75
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 are affected by hearing loss.195 Given the large number of people affected, and the 
foreseeable rise in this number as the elderly population grows, it is of imperative 
importance to seek medical technologies that restore hearing to these individuals.  
 In mammals, hearing is achieved by converting sound waves to vibrations that are 
detected in the inner ear.  Within the inner ear, distinct vibration frequencies excite 
specific hair cells lining the turns of the cochlea.  The excited hair cells are able to 
translate the vibrations to electrical signals and transmit them to the central nervous 
system for processing through the inner hair cell-auditory nerve synapses.196 The loss of 
hearing, whether stemming from noise, ototoxic drugs, and/or aging, is typically caused 
by oxidative stress, which is the overproduction of reactive oxygen species (ROS) in the 
cell.195, 197, 198 Numerous studies have focused on the use of therapeutics to counteract the 
overproduction of ROS as a means of preventing deafness in individuals, especially since 
deafness can occur anywhere from hours to weeks, month, or even years after the 
occurrence of the initial trauma.199-201 Some of the main therapeutic methods used for the 
prevention of deafness include antioxidant drugs (salicylate,201 allopurinol,202 iron 
chelators,203 ebselen,204 or N-acetylcysteine205), heat shock proteins,206 neurotrophic 
factors207 (GDNF,207-209 NT-3,210 and BDNF211), and gene therapy.212  While the use of 
antioxidative drugs and neurotrophic factors (systemically or locally) has been 
successful,201, 207 the use of heat shock proteins and/or gene therapy has proven to be 
more difficult due to the incomplete understanding of the signaling pathways involved or 
the inability to target the therapies to specific sites in the cochlea.213, 214       
 In events when deafness cannot be adequately prevented, or for those individuals 
born with this condition, the inner hair cells are either severely damaged or completely 
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destroyed.195 In such cases, cochlear implants are the choice method of therapy due to 
their ability to directly stimulate the auditory nerves and return some level of hearing for 
most individuals. With the advent of new technologies and a better understanding of 
cochlear physiology, more advanced cochlear implants with multiple channels have been 
developed in recent years that can provide a more enhanced and functional level of 
hearing to most individuals.  Due to the success of cochlear implants in individuals with 
severe to complete hearing loss, individuals with a lower degree of hearing loss have 
recently qualified to use these devices.195, 215 In these individuals, a certain percentage of 
the inner hair cells, and thereby the inner hair cell-auditory nerve synapses, are still 
functional and are able to translate & transmit sound vibrations to the central nervous 
system for processing. Unfortunately, studies show that the trauma induced by the 
insertion of cochlear implants increase the level of ROS216 and often bring about the 
death of these remaining hair cells.  The death of these hair cells destroy any remaining 
hearing the individual had maintained and force them to completely rely on the device.215, 
217 Recent studies have focused on the use of ROS preventative therapeutics to reduce the 
trauma from implant insertion and thereby increase the levels of hearing for these 
individuals.216 
 Current studies that focus on combining preservative measures and cochlear 
implant insertion to increase the hearing level of patients use therapeutics for the 
reduction of ROS as mentioned previously.  From among these, the studies that involve 
neurotrophic factors have been most successful.  These studies have used a variety of 
methods to deliver these factors either prior, during, or after the implant insertion.  
Kanzaki et al. has shown that the infusion of adenoviral vectors encoding a transgene for 
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GDNF (Glial cell Derived Neurotrophic Factor) at the time of surgery could significantly 
improve inner hair cell survival over a 43-day period.218 Similarly, Yamagata et al. used a 
cannula-osmotic pump system loaded with BDNF (Brain Derived Neurotrophic Factor) 
with similar results.  Animals receiving the neurotrophic factor had a higher rate of cell 
survival and scored significantly lower in the auditory brain stem response (ABR) 
recordings (where a lower score represents a more physiological state).211 However, 
while both of these methods have worked well in animal studies, implementing them on 
humans has proven to be difficult.  As with all gene-therapies, adenoviral vector 
treatment poses unknown side-effects due to an incomplete understanding of the 
mechanisms involved and the use of cannula-osmotic pump systems or mini-osmotic 
pumps is cumbersome and prone to cause infections.195 The use of a delivery system 
capable of the continuous release of such neurotrophic factors and antioxidant drugs used 
in conjunction with the cochlear implant could prove to be a novel solution for this case.      
   
 
5.2 Experimental Methods 
 
5.2.1 Materials 
 
 Dextran, chloroform, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 
pyridinium p-toluenesulfonate, 2-methoxypropane triethylamine, acetic acid, sodium 
acetate, phosphate buffered saline (PBS), poly[tris(2,5-bis(hexyloxy)-1,4-
phenylenevinylene)-alt-(1,3-phenylenevinylene) (PTDPV), poly[(m-phenylenevinylene)-
	   112 
alt-(2,5-dihexyloxy-p-phenylenevinylene)] (MEHPV), heparin sulfate, and tween 20 
were used as purchased from Sigma Aldrich, USA. Polylactide-co-glycolide (PLGA) 
with a ratio of 50:50 lactide to glycolide and a molecular weight of 44 kDa was 
purchased from Lactel Corporation. Piribedil was purchased from Ontario Chemicals and 
Glial Derived Neurotrophic Factor (GDNF) was a generous gift from MedGenesis 
Therapeutix, Inc. 
 
 
5.2.2 Fabrication of Multifunctional Particles for Cochlear Delivery 
  
 Polymer 13, a high molecular weight acetal dextran (70 kDa), was graciously 
synthesized by Dr. Tae-Hong Park and Nathan Jones, following a well established 
method.41 Tricompartmental particles with one compartment composed of PLGA (50:50, 
40 kDa, 10% w/v) and two compartments composed of polymer 13 and PLGA at a ratio 
of 65:35 and a total concentration of 7% were fabricated using the EHD co-jetting 
method. Here a lower overall percentage of polymers were used in the two similar 
compartments due to the higher molecular weight of the dextran polymer used. For the 
animal studies, particles with a blue dye in all three compartments were employed that 
could easily be identified in fluorescent microscopy.  
 To fabricate particles with piribedil, a 2% w/w amount of the drug was mixed into 
the jetting solution in the PLGA compartment. For the fabrication of particles with 
heparin, polymer 4 at a 25% w/w was incorporated in the two similar compartments. The 
particles were placed in pH 5 for 10 hrs to create porosity on two-thirds of the particles 
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and were then incubated with heparin overnight. After the incubation, the particles were 
UV’ed for 2 hours at 365 nm to cross-link the heparin to the benzophenone groups of 
polymer 4 in the particles via photoreactive chemistry. The particles were washed 
numerous times to remove the unreacted heparin and were then stored in PBS for further 
analysis. Zeta potential measuremnts were done to confirm the attachment of the heparin 
to the microparticles. To determine the optimal loading of GDNF onto the heparin 
labeled particles, GDNF at three different concentrations (25, 75, and 150 µl) were 
incubated with particles for 3, 6, and 24 hours (total 9 samples). At each time point, the 
particles were washed, labeled with primary and secondary antibodies against GDNF, 
and the samples’ fluorescence was measured with a plate reader. 
  
 
5.2.3 Persistence and Compatibility Testing of Particles In Vivo 
  
 Animal studies in guinea pigs with microparticles were done in Professor 
Altschuler’s group by Dr. Astin Ross and Diane Prieskorn and the details are included in 
Appendix D. 
 
 
5.2.4 Release of Therapeutics from Microparticles 
 
 To determine the release of Piribedil, the jetted particles were collected into four 
20 mg samples and suspended in five ml of pH 5 buffer for 10 hours at 37 oC to create 
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pores in the particles. The particles were then washed with PBS and 1% v/v Tween 20, 
re-suspended in 5 ml of PBS, and placed in a 100-kDa dialysis membrane.  The 
membrane was inserted into a Falcon tube containing 35 mL of the same buffer and 
gently shaken at 37 oC.  At predetermined intervals, the tubes were removed from the 
incubator, the membranes were inserted in new tubes with 35 mL of fresh buffer, and 
replaced back in the incubator.  The drug containing buffers in the Falcon tubes were then 
measured via a UV Visual spectroscopy machine to determine the amount of drug 
released based on a previously done calibration curve.   
 To determine the release of GDNF, 12 mg of particles were labeled with heparin 
and were then divided into 4 groups of 3 mg each. The volume was adjusted to 250 µl 
and 125 µg of GDNF was added to each sample. The volume was brought to 500 µl to 
make an effective 250 µg/ml concentration of GDNF for 6 mg/ml of particles. The 
particles were incubated with the GDNF for 6 hours, followed by multiple washes to 
remove unbound material. The final buffer solution (sterile PBS with 0.1% tween 20) 
was brought to a volume of 1 ml and the samples were incubated in a 37 oC incubator. At 
predetermined time intervals, the samples were removed and  centrifuged at 4000 RPM 
for 2 min to gently pellet the particles. The supernatant was removed & frozen, the 
samples were washed to remove the free GDNF in the solution, and the samples were 
placed back in the incubator. The frozen samples were measured via an ELISA kit for 
GDNF from Abcam ® by Joel Whitfield. 
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5.3 Results and Discussion 
 
 To design multifunctional particles for cochlear delivery, a combination of the 
techniques developed in Chapters 2-4 were employed. The parameters for a successful 
carrier system included (i) the incorporation of piribedil (to reduce trauma-induced 
apoptosis) and its release over a 2-4 week period; (ii) the encapsulation, protection, and 
release of GDNF (to help with neural survival & elongation) for a 1-2 month period; (iii) 
establishment of the general biocompatibility of the particles in the cochlea; (iv) and the 
persistence of the particles within the time-frame of the study in the cochlea. To this end, 
tricompartmental particles were engineered through the EHD co-jetting method, where 
one compartment was composed of PLGA and piribedil, while the other two 
compartments were composed of PLGA, polymer 4 (benzophenone-functionalized 
PLGA), and polymer 13 (a high molecular weight acetal dextran) (Figure 5-1). The 
piribedil-containing compartment was designed to meet the first requirement mentioned 
above, where the release of the therapeutic was expected to span over a 15-20 day period 
based on previous studies with a similar molecular weight therapeutic (irinotecan) in the 
same polymer in section 4.3 of this dissertation. The polymers chosen for all 
compartments were biocompatible or biodegradable and thus should not have caused any 
MPS signaling or inflammation on their own in the cochlea. Additionally, the large size 
of the particles (6-8 µm) were chosen to delay uptake in the presence of any potential 
macrophages (the cochlea does not typically have resident macrophages). Moreover, the 
polymers, if biodegradable, were chosen to have a degradation rate that exceeded the 
time requirements for the persistence in the cochlea.  
	   116 
 Lastly, but most importantly, the incorporation and release of GDNF from the 
particles was designed. This was not a simple matter, as growth factors are easily prone 
to degradation: the direct incorporation of GDNF in the jetting solutions would result in 
the denaturation of the growth factor in the organic solutions and, while some studies 
have successfully incorporated proteins in PLGA particles, the degradation of the 
polymers and the associated acidic pockets, typically denature the proteins during the 
release phase.219 To address this challenge, the particles could be functionalized with 
heparin, which is well established for its interactions with various growth factors that can 
be employed for the loading and release of the GDNF, and its ability to shield the GDNF 
from degradation during this time.220-223 To accomplish this, particles containing polymer 
4 and 13 were designed, where the release of polymer 13 via incubation in a pH 5 buffer 
would create pores in the particles and increase the surface area, while the benzophenone 
groups in polymer 4 could potentially be used to cross-link the heparin to the surface of 
the particles. A full schematic of the designed particles is demonstrated in Figure 5-1.  
Figure 5-1: Design of multifunctional particles for cochlear delivery.  
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 To begin, the unloaded particles were analyzed to determine their size 
distribution, release of dextran, and their level of porosity (Figure 5-2). Similar to 
particles in 3.3 with polymer 8 (low molecular weight dextran acetal), the as-fabricated 
particles have a negative zeta potential measurement (~25.5 mV ± 0.8) due to the free 
hydroxyl groups available in polymer 13. Upon pH 5 incubation and the release of the 
dextran from the particles, the remaining porous particles composed primarily of PLGA 
have a less negative zeta potential value (-13 mV ± 2.8), which confirms the release of 
the dextran. Further evidence of the release of polymer 13 from the particles in the acidic 
environment is shown in Figure 5-2C where SEM images of the particles clearly 
demonstrate the creation of pores over a period of time in the bulk of the particles. Here, 
the desired level of porosity (before further degradation of the particles) is achieved at 10 
hours in comparison to the 5 hours previously observed with the lower molecular weight 
Figure 5-2: Characterization of unloaded particles. (A) The zeta potential measurement of the particles 
before and after pH 5 incubation, (B) the size distribution of the particles based on SEM images, and 
(C) the degree of porosity as a function of time. 
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polymer 8, which is as expected: the longer chained molecules in this case will move at a 
slower speed out of the polymer matrix of the particles as compared to the smaller 
chained molecules in the previous study. The size distribution of the microparticles 
(Figure 5-2B) demonstrates relatively uniform particles at 7.8 ± 1.4 µm. 
  Once the characterization of the particles was established, the persistence and 
general compatibility of the particles on their own within the cochea was examined. This 
was especially important since the persistence and continuous release of the therapeutics 
within the cochlea is important for the survival of the hair cells. Here, blue-labeled 
particles were injected at the base of the cochlea and after one or seven days the animals 
were sacrificed and their cochlea were dissected and imaged via 2-photon microscopy 
(Figure 5-3). Figure 5-3B-C are the three dimensional reconstruction of the 2-photon 
Figure 5-3: Persistence of particles within the cochlea. (A) Schematic describing the procedure used to 
infuse the particles into the cochlea, and a cartoon of a cross section of the cochlea outlining the site of 
injection and its individual turns. (B-C) 3D reconstruction images of particles within the cochlea after 1 
and 7 days, respectively. (D) The particle distribution within the cochlear turns.  
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images of particles from the basal section of the cochlea, clearly demonstrating the 
presence of particles within the cochlea after one or seven days. The table (Figure 5-3D) 
contains individual particle counts from three sections in center of the cochlea, showing a 
representative distribution of the particles within the cochlear turns for both days. The 
majority of the particles are located near the base (Turn 1) of the cochlea for both days 
and at similar concentrations, potentially implying that the particles that survive the first 
24 hours post-infusion remain in the cochlea for a prolonged period. Additionally, the 
distribution of the particles in the first turn is ideal for our case since the majority of the 
damage to the hair cells occur in this region. Figure 5-4 contains individual images of 
particles within each of the cochlear turns at the one-day period for reference. Here again, 
a similar trend can be observed where the majority of the particles are seen in the fist 
channel followed by lower percentages in the turns closer to the apex. 
 
 
 In addition to determining the persistence of the particles within the cochlea, we 
were also interested in determining whether the presence of the particles altered any 
detectable functioning abilities of the cochlear components. To test this, an ABR 
(auditory brainstem response) test was performed (Figure 5-5). In this test, sound is 
Figure 5-4: Persistence of particles within the cochlea. (A-D) representative images of each of the turns 
of the cochlea showing the distribution of the particles (blue) in each. 
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given at various decibels in specific sets of frequencies to animals and their electrical 
impulses (time response of neurons) are recorded. In these studies, a significant (greater 
than 15-20 dB) shift in the recorded responses signifies a potential damage to the hair cell 
functioning and viability. Here, animals were tested at three different frequencies (4, 8, 
and 20 kHz), infused with particles, and retested after seven days. The shifts at all 
measured frequencies were well below the acceptable limit, potentially signifying that the 
presence of particles in the cochlea does not interfere with cochlear components. 
 Upon characterizing the microparticles and confirming the persistence of the 
particles in animals, the continuous release of the anti-oxidant therapeutic, piribedil, from 
the microparticles was assessed. The pH of the fluid within the microenvironment of the 
cochlea, the perilymph fluid, is at neutral pH and since a continuous release over a 10-20 
day period is most optimal for the release of the anti-oxidant therapeutic following 
surgery and the insertion of the cochlear implant, release from a 44 kDa PLGA polymer 
was chosen.  Particles composed of PLGA and piribedil in one compartment and PLGA 
and polymer 13 in the other compartments were fabricated following the EHD co-jetting 
Figure 5-5: ABR testing of guinea pigs after particle infusion into the cochlea. (A) Representative 
schematic of the procedure and (B) ABR analysis done at various frequencies. 
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procedure. The particles contained a green dye in the piribedil containing compartment 
and a blue dye in the PLGA/polymer 13 compartments. Figure 5-6A demonstrates the 
compartmentalization of these particles. Here, Piribedil auto-fluoresced in the red 
channel, and this was used as a method to confirm the compartmentalization of the drug. 
As can be seen in the middle and right images, the red channel overlaps with the green 
channel (middle) and is completely separate from the blue channel (right), confirming the 
encapsulation of the therapeutic in the selected compartment. To determine the release 
kinetics of the piribedil from the therapeutic system, particles were incubated at 37 oC in 
a phosphate buffered saline solution and at pre-determined intervals samples were taken 
of the released material and measured via UV visual spectroscopy to determine the 
amount of pribedil released. As demonstrated in Figure 5-5B, the release of piribedil 
Figure 5-6: Encapsulation and release of piribedil from particles. (A) Schematic showing the location 
of each component in the particles, and individual channels showing the encapsulation of piribedil (red) 
in the green compartment. (B) The continuous release of piribedil from particles over a 14-day period. 
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from the particles is continuous over a 14-day period, which is ideal for the release of the 
anti-excitotoxic therapeutic. 
 Next, we were interested in incorporating a neurotrophic factor into our particles. 
As previously mentioned, a great challenge in this field is the encapsulation and release 
of the proteins, especially growth factors, without denaturing them in the process. Tri-
compartmental particles with PLGA, polymer 4, and polymer 13 in two compartments 
and PLGA in one compartment were fabricated according to our original design. The 
particles were incubated in an acidic environment to create pores in the system, which 
increased the effective surface area of the particles. The particles were then incubated in a 
heparin solution, which allowed the heparin molecules to infiltrate into the pores of the 
microparticles. The particle/heparin mixture was then exposed to UV light, which cross-
linked the heparin to the polymer 4 in the particles via photoreactive chemistry (Figure 
5-7). Zeta potential measurements were done to confirm the attachment of the heparin to 
the surface of the particles. As shown before, the zeta potential measurements of the 
particles become less negative after pH 5 incubation and the creation of the pores. After 
heparin attachment, however, the zeta potential of the particles is more negative again 
due to the negatively charged groups on the heparin. After heparin attachment, the 
particles were incubated with GDNF, which is known to associate with heparin. After 
loading the particles with GDNF, antibody staining was done to confirm the presence of 
the growth factor selectively on one side of the particles (Figure 5-7B). Here, the PLGA 
only compartment contained a green dye, the heparin compartment contained a blue dye, 
and the GDNF is labeled with a magenta dye (Alexa 647 goat anti-rabbit). The three-
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dimensional reconstruction of the particles clearly display the compartmentalization and 
presence of GDNF on the particles. 
 Further studies were done to determine the optimal condition for the loading of 
GDNF into particles (Figure 5-8). Here, heparin functionalized particles were incubated 
with three concentrations of GDNF (25, 75, and 150 µg/ml) and their individual loadings 
into particles were measured at three incubation time points (3, 6, and 24 hours). To 
determine the relative amount of GDNF loading, the particles were washed after each 
incubation, then labeled with primary and secondary antibodies against GDNF, where the 
Figure 5-7: Incorporation of heparin and GDNF on the particles. (A) Zeta potential measurements of 
particles before/after dextran release and after heparin attachment. (B) CLSM images of particles 
loaded with GDNF and labeled with a magenta secondary antibody and (C) their 3-D reconstruction 
showing the compartmentalization of the GDNF. 
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secondary contained a fluorescent molecule. The solutions containing the particles were 
then measured using a plate reader to determine the relative fluorescent intensity of each 
sample, which is directly proportional to the concentration of secondary antibody and 
thereby the GDNF incorporated into each particle set. As expected, increasing the initial 
concentration of GDNF incubated in the particles resulted in an increase in the amount of 
GDNF loaded into the particles, where a plateauing effect is not observed for the 
concentrations tested. Base on this, a high loading of GDNF can be achieved using our 
designed particles, which is therapeutically desirable as it requires a lower number of 
particles per injection. Additionally, the optimal incubation time was also determined for 
this study to potentially be at 6 hours, since shorter incubation times do not allow 
sufficient time for the incorporation of the GDNF into the particles and longer durations 
result in the denaturation of the majority of the GDNF, as observed by the significant 
decrease in the detected amounts at 24 hours.  
 
Figure 5-8: Determining the optimal conditions for GDNF loading onto particles. The fluorescent 
intensity of labeled GDNF at three different concentrations and three incubation time points were 
measured with a plate reader to determine the optimal conditions for the maximum loading of GDNF 
into particles. 
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 Once the optimal loading conditions for GDNF had been established, the release 
of GDNF from particles was investigated. Here, the particles were loaded with GDNF, 
washed to remove unreacted material, and incubated at physiological conditions. At 
various time points, the samples were pelleted and the supernatant containing the released 
GDNF was frozen. These samples were then measured via a GDNF specific ELISA 
(Enzyme Linked Immunosorbent Assay) to determine the precise amount of GDNF 
released at each time point. Figure 5-9 shows the release of GDNF over a 30-day period, 
which shows the successful and continuous release of the growth factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-9: Release of GDNF from particles. The release of GDNF as determined based on ELISA 
measurements over a 50 day period is demonstrated.  
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5.4 Summary 
 
 Multicompartmental particles loaded with multiple therapeutics are an ideal 
carrier system for delivery to the cochlea where the distinct release of each factor is 
desired. In this chapter, the design of particles loaded with a small molecule drug and a 
growth factor for cochlear delivery are explored. The characterization of the base 
particles and the In Vivo persistence and distribution of the microparticles throughout the 
cochlea after a one- or seven-day period are shown. The selective loading of a small 
molecule therapeutic and its controlled release is demonstrated. In addition, a novel 
approach for the loading, protection, and release of a growth factor using heparin 
functionalized particles is investigated. Together, these results suggest that the 
methodologies developed in the previous chapters of this dissertation can successfully be 
employed for the design of multifunctional particles for specific applications. 
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CHAPTER 6 
Conclusions and Future Directions 
 
 Throughout this dissertation, the fabrication of multifunctional particles via the 
EHD co-jetting procedure, methodologies for the programming of specific physical and 
chemical characteristics, and the use of functional polymers for the responsive release of 
therapeutics is investigated. Additionally, the application of these techniques for the 
design of multifunctional particles for the delivery of multiple factors to the cochlea is 
explored. While these strategies have led to the composition of a toolbox for the design of 
particles for specific applications, the actual use of these strategies beyond the fabrication 
of particles for cochlear delivery is yet on-going. Below, specific outlooks for each of this 
dissertation’s chapters are discussed. 
 
 
6.1 Applications for the Surface Modification of Particles 
 
 The attachment of targeting ligands and stealth moieties to the surface of particles 
was explored in chapter 2, where the attachment of folic acid, iRGD, and PEG to distinct 
patches was demonstrated. Beyond the simple attachment of these molecules to the 
surface of particles, further studies into the effect of multi-valency and avidity (multiple
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factors of the same targeting molecule or the cooperation of multiple factors, 
respectively) can also be further studies. Here, the ligand density of the particles can both 
be controlled based on the concentration of targeting ligands used (up to the saturation 
point of the functional groups on the surface) or by using different ratios of functional 
polymers to internally control the maximum number of functional groups present on the 
surface. By having good control over the ratio of the ligand molecules used, one can 
establish and sequentially test the effect of ligand concentration on targeting and 
circulation. Additionally, an important factor in designing the surface of nanoparticles is 
the ratio between the stealth and targeting molecules. Several design parameters exist, 
such as: i) isotropic particles with a mixture of both types on the surface using the same 
ligand chemistry; ii) isotropic particles with a mixture of both types on the surface where 
the ratio is well established due different ligand chemistries; iii) anisotropic particles with 
specific patches for each of the ligands; iv) anisotropic particles with specific patches 
where some have a mixture of the two, and some have just the stealth ligands on the 
surface. Each of these scenarios has their advantages and disadvantages, and a solid 
understanding of which system is optimal is lacking based on the current literature. The 
testing of such particles could lead to not just finding a more effective therapy, but also a 
better understanding of how opsonization and targeting mechanisms occur in the body. 
 In addition to controlling the ratios of stealth and targeting ligands on the surface 
of carrier systems, one could also think about testing the effect of multiple ligands. The 
cooperative effect of multiple ligands, and the effect of the valency of each, could 
potentially be tested by using patchy particles where each patch represents a specific 
ligand. For example, for cancer therapy a ligand could be used for targeting to the 
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vasculature near the tumors, another could be used for targeting to the cancer cells, and 
yet another for penetration within the tumor. Additionally, targeting within the cell to the 
correct site could also be explored. It might be that through the use of such design 
parameters, particles can be fine-tuned and optimized for their specific applications. 
 While the design of such systems is very possible using the EHD co-jetting 
system, the downstream effects of covering the entire surface of these particles with 
targeting ligands must also be considered. While additional targeting ligands might make 
the particles more specific and, as a result, potentially more effective systems, if the 
increase in the targeting ligands results in a decrease in the stealth ligands and 
compromises the circulation time of the particles, the system might not have sufficient 
time to get to the target site. As a result, the design of such systems is not an effortless 
task, but rather can be ambiguous and requires the consideration of various parameters. 
 In addition to the use of selective surface modification for targeting to specific 
sites in the body, such surface modification could also potentially be used for the capture 
of circulating tumor cells. Circulating tumor cells (CTCs) are typically present in 
extremely low numbers in the blood of most patients suffering from metastatic cancer 
and have been hypothesized to be the origin of the intractable metastasis of the tumor to 
other locations in the body.224 As a result, the capture and study of these cells is an 
important step in developing a therapy for metastatic cancers. Most CTCs have been 
noted to overexpress EpCAM (epithelial cell adhesion molecule)225, 226 and material 
functionalized with anti-EpCAM antibodies have the potential to target to these rare cells. 
In collaboration with Professor Nagrath’s group in the Chemical Engineering department, 
we were interested in using particles coated with anti-EpCAM antibodies along with their 
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well-established microfluidic devices as a means for the capture and further purification 
of CTCs from patient blood samples. 
 Here, the surface of particles containing PLGA, polymer 6, and polymer 8 were 
sequentially functionalized with azide-PEG-biotin, neutravidin, and biotin conjugated 
anti-EpCAM (Figure 6-1). The particles were then labeled with a secondary antibody 
and their specific attachment was evaluated against particle that were not incubated with 
the biotin anti-EpCAM molecule. The particles containing anti-EpCAM were clearly 
labeled with the secondary antibody (Figure 6-1B, where the inset is a 3D reconstruction 
of the particles from  CLSM images and shows complete coverage by the antibody), 
Figure 6-1: Functionalization of particles with anti-EpCAM. (A) Schematic of the steps taken to 
functionalize the surface with anti-EpCAM and (B-C) secondary antibody labeling of particles to 
determine the attachment. Here the anti-EpCAM labeled particles fluoresce in the red channel (B), 
while the control particles are not labeled (C). The inset in (B) is a 3D reconstruction of the particles 
showing complete coverage by the anti-EpCAM molecule. 
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while the controls did not have any staining from the secondary antibody (Figure 6-1C).  
 While the surface functionalization of these particles has been established, the 
testing of these particles to determine their ability in capturing CTC’s is yet to be 
determined. Additionally, the procedure established here could easily be extended to 
other targeting molecules that are labeled with biotin. This introduces a method for the 
functionalization of particles with antibodies that may be prone to denaturation through 
the common attachment of proteins via EDC/Sulfo-NHS chemistries.  
 
 
6.2 Testing the Effects of Physical Properties on Particle Functionality 
 
 The programming of physical properties of particles such as shape, size, charge, 
and texture were extensively studied in Chapter 3. Going forward the effect of such 
physical properties on the functionality of particles in the body need to be tested. While 
the ability to impart multiple properties has been explored, they each need to be 
examined to determine their potential suitability for their specific applications, especially 
how they fair in circulation. This is especially difficult to accomplish without the use of a 
large number of animals. 
 A potential method for testing the behavior of particles in blood is the use of 
Nanoparticle Tracking Analysis (NTA) technology with a Nanosight device, which tracks 
individual particle sizes based on their diffusion rate. While similar techniques used for 
size determination would detect both particles and plasma components, the Nanosight 
will be able to differentiate the particles based on their fluorescent signal. Here a proof of 
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concept study was done to determine the feasibility of this idea. Purchased, green 
fluorescent particles were incubated in serum and their size distribution as a function of 
time was studied (Figure 6-2). It can clearly be seen that at longer time-points the 
average diameter of the particles increase as a layer of proteins attach to the surface 
(opsonization) and eventually form some aggregate. Going forward, this approach could 
be applied to the testing of the effect of various physical properties in serum to determine 
the feasibility of particle sets before testing them animals. 
 
 
 
 
 
Figure 6-2: Effective size of nanoparticles in serum. Nanoparticles were incubated in serum for 15 min, 
1 and 14.5 hours and their effective size range was determined using Nanosight. The colored lines 
signify the average size while the black lines are the standard deviations per size derived from 6 runs of 
over 3-4 thousand tracked particles. 
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6.3 Toward Dual Release of Therapeutics 
 
 In chapter 4, the on-demand degradation and responsive release of therapeutics 
using functional polymers was explored. However, while both the degradation and 
release of therapeutics from polymer 2 and polymer 8 were established, dual responsive 
release of therapeutics from polymer 11 has not been explored. In addition, the release of 
more than one small molecular weight therapeutic with distinct kinetics from the same 
particle set is yet to be determined. Here, one of the major challenges was the 
encapsulation of small molecular therapeutics in select compartments. While these 
therapeutics stay compartmentalized at lower concentrations (for example irinotecan and 
piribedil at 2% w/w), most therapeutics will diffuse into the second compartment during 
the jetting procedure due to their small size. While an exception to this in a specific case 
(section 3.3) has been studied, the majority of therapeutics, especially in PLGA polymers, 
are not compartmentalized at higher concentrations (Figure 6-3A). To this end, a particle 
system with a third, middle compartment composed of a high molecular weight, 
Figure 6-3: Compartmentalization of therapeutics in particles. In bi-compartmental particles, 
therapeutics at high encapsulation rates (here 25% w/w) diffuse to the other compartment during the 
jetting process (A). Incorporation of a ‘barrier’ compartment composed of a high molecular weight, 
hydrophobic polymer reduces the rate of diffusion and results in compartmentalized therapeutics even 
at high concentrations. 
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hydrophobic polymers was fabricated. Here, this compartment acted as a “barrier” to 
prevent the diffusion of the therapeutic to the other compartment. As shown in Figure 6-
3, irinotecan (autofluorescing in the blue compartment) is not compartmentalized in the 
bi-compartmental particles, meaning that blue is also seen in the green compartment, 
while it is compartmentalized in the tri-compartmental particles with a barrier 
compartment in between, signified by the blue and green dyes that do not overlap. This 
technique could potentially be used for the fabrication of particles with multiple drugs 
encapsulated in separate compartments for the establishment of dual, distinct release of 
therapeutics.  
 
 
6.4 Towards Multiple Protein Delivery  
 
 The design of multifunctional particles for cochlear delivery was examined in 
detail in Chapter 4, and the fabrication of such particles and their testing for release of 
multiple factors was established. Looking forward, the feasibility of such drug loaded 
particles in animals needs to be explored. Such testing needs to include appropriate 
controls and examine the effect of the release of each therapeutic individually, combined, 
and delivered in a different method as a control (for example via an osmotic pump) to 
determine the advantages and disadvantages of the multifunctional particles. 
 In addition, while the techniques established for the incorporation of GDNF in 
particles using heparin works well because of the strong interaction between heparin and 
the growth factor, this strategy cannot always be applied to other growth factors and 
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proteins, especially if they do not have the appropriate binding sites to establish 
interactions with heparin. As such, other techniques for the incorporation of growth 
factors should be investigated. A possible strategy is the development of core-shell type 
particles where the center compartment is composed of a water-soluble core and the shell 
is composed of PLGA (Figure 6-4). This could potentially allow for the incorporation of 
a small molecule therapeutic, like piribedil, in the shell of the particles, while allowing 
for the incorporation and protection of the protein in the core. The release of the 
therapeutics would then depend on their diffusion through shell compartment. Here 
preliminary studies with core-shell particles and their characterization (Figure 6-4B-C, 
SEM & TEM (transmission electron microscopy), respectively) are demonstrated. 
Further analysis with regards to the encapsulation and release of proteins is needed to 
determine the feasibility of this system as an alternative method to the current established 
use of heparin. Additionally, the combination of both techniques could potentially result 
in particles with multiple protein release kinetics both for heparin binding growth factors 
and other types of proteins.  
 
 
 
 
 
Figure 6-4: Fabrication of core-shell particles. (A) Here the shell is composed of PLGA and the core is 
composed of a water-soluble compound, such as PEG or albumin. (B-C) SEM and TEM analysis of the 
particles. For the TEM images, iron oxide nanoparticles were encapsulated in the shell to provide a 
contrast for the imaging. The particles were embedded in paraffin, then sections at 100 nm before 
mounting for TEM analysis. 
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6.5 Future Outlook 
 
 The work established in this dissertation has lead to the formation of a toolbox 
that can be used for the design of multifunctional particles with programmable properties 
for individual applications. While this work explored the design of particles for cochlear 
delivery, future investigations could focus on the use of these parameters for the design 
of multifunctional particles for applications such as cancer therapy, cardiovascular 
disease diagnosis, and Alzheimer therapy. Each of these individual applications has their 
own unique requirements and particles need to be optimized for each separately. More 
importantly, each particle set needs to be validated for their specific desired parameters. 
Certain tools already exist, however, the majority relies on the injection of particle into 
animals to determine their fate. While this is a valid method for characterizing a particle 
system’s functionality as a whole, it does not allow for the understanding of which 
specific physical properties are determining its functionality. To validate the particles for 
such applications, In Situ tools that eliminate the use of a large number of animals and 
delays in deciphering the optimal properties for particles need to be developed.  
 
 
 
 
 
 
 
	  Appendix A 
Synthesis and Characterization of Functional Poly (Lactide -co-Glycolides) 
 
The synthesis and full characterization of functional polymers used were graciously done 
by Dr. Sampa Saha and Dr. Hakan Durmaz. 
 
Monomer A Synthesis: 
Monomer A has been synthesized using the literature reported procedure.131  
 
 
 
Random copolymer synthesis (Scheme 2-1):  
 Ring-opening co-polymerizations of monomer A and l-lactide were performed in 
the melt using benzyl alcohol (BnOH) and Sn(Oct)2 as the initiator and catalyst, 
respectively. Briefly, monomer A (4.56 g, 19.3 mmol) and recrystallized l-lactide (2.78 g, 
19.3 mmol) were placed in an oven dried Schlenk flask equipped with a small stirring bar 
under a dry argon atmosphere. BnOH (10.5 mg, 0.1 mmol) and catalyst Sn(Oct)2 (39.6 
mg, 0.1 mmol) were added by an argon purged dry syringe, and the flask was kept under 
Monomer	  A	   Polymer A Polymer 2 
Scheme 2-1: Synthesis of the hydroxylated poly (lactide-co-glycolide) 
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  vacuum for 2 hours. The flask was then closed and immersed in an oil bath thermostated 
at 110 °C for 4 hours. The resulting polymer A was dissolved in dichloromethane, 
precipitated in cold methanol, and dried in vacuum. Polymerizations proceeded in good 
yield (90%). 1H NMR: (CDCl3) δ: 1.5-1.7 (m, 6H), 3.8-4.0 (m, 2H), 4.5-4.6 (m, 2H), 4.6-
5.0 (m, 2H), 5.1-5.3 (m, 2H), 5.4-5.5 (m, 1H), 7.2-7.4 (m, 5H). 
 Deprotection of Polymer A to yield Polymer 2 has been done using literature 
reported procedure.131 The yield of the final polymer 2 was around 80%. Found Mn: 
46333; Mw: 52883; PDI: 1.14; (Molecular weight has been determined by GPC using 
polystyrene as calibration standard). Polymer 2 characterizations: 1H NMR: (CDCl3) δ: 
1.5-1.7 (m, 6H), 3.8-4.0 (m, 2H), 4.6-5.0 (m, 2H), 5.1-5.3 (m, 2H), 5.4-5.5 (m, 1H). FT-
IR: ν = [1100, 1300, 1190, 1200, 1260, 1350, 1380, 1400, 1450, 1770, 2920, and 2980 
cm-1]. Raman: ν = [1440, 1750, 2876, 2900, 2943, 3000 cm-1]. 
 
 
Functionalization and characterization of polymers 3, 4, and 5 (Scheme 2): 
 
 Functionalized poly-lactide derivative 3: Compound 2 (3-(diphenylphosphino)-4-
(methoxycarbonyl) benzoic acid) was synthesized according to the literature reported 
protocol.132 56 mg of compound 2 was dissolved in 1 ml of dry dichloromethane under 
dry argon atmosphere. Then 42 mg of DCC (dicyclohexyl carbodiimide) and 12.5 mg of 
DMAP (N,N dimethyl amino pyridine) was added to this solution. The solution was 
stirred for 10 min, then 15 mg of polymer 2 was added under argon and stirred for 
overnight at RT. Next, all the solvents were evaporated to dryness. Then the resulting 
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  polymer 3 was dissolved in minimal amount of dichloromethane, precipitated in cold 
methanol, and dried in vacuum. Functionalization proceeded in good yield at 90% 
conversion. This polymer is air sensitive and after work up we found that around 20% of 
triphenyl phosphine functionality of polymer 3 was converted to its phosphine oxide 
analogues. Hence, we stored the polymer in oxygen free atmosphere (vacuum dessicator) 
for future use. We have used this mixture of polymers (70% polymer 3, 20% phosphine 
oxide analogue of polymer 3 and 10% polymer 2) for subsequent study.  
Scheme 2: Synthesis of poly (lactide-co-glycolide) derivatives. 
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  Polymer 3 characterization: 1H NMR: (CDCl3) δ 1.42-1.67 (bs, 6H), 3.62-3.82 (s, 3H), 
4.42-4.97 (m, 4H), 5.02-5.3 (m, 2H), 5.38-5.58 (bs, 1H), 7.18-7.78 (m, 13H). 31P NMR: 
(CDCl3) δ: -4.3 ppm. FT-IR: ν = [1100, 1200, 1180, 1260, 1280, 1350, 1380, 1430, 1580, 
1730, 1760, 2940, and 2980 cm-1]. Raman: ν = [1430, 1596, 1732, 2896, 2900, 2943, 
2977, 3057 cm-1].  
 Functionalized poly-lactide derivative 4: Compound 1 (2-(4-benzoylphenyl) 
acetic acid) was synthesized according to the literature reported protocol.133 35 mg of 
compound 1 was dissolved in 1 ml of dry dichloromethane under argon atmosphere. Then 
42 mg of DCC and 12.5 mg of DMAP was added to this solution. The solution was 
stirred for 10 min, then 15 mg of polymer 2 was added under argon and stirred for 
overnight at RT. All solvents were evaporated to dryness, then the resulting polymer 4 
was dissolved in minimal amount of dichloromethane, precipitated in cold methanol, and 
dried in vacuum. Functionalization proceeded in good yield at 100% conversion. Polymer 
4 characterization: 1H NMR: (CDCl3) δ 1.42-1.71 (bs, 6H), 4.58-4.97 (m, 4H), 5.05-5.25 
(m, 2H), 5.5-5.7 (bs, 1H), 7.39-7.55 (bs, 2H), 7.55-7.65 (bs, 1H), 7.70-7.9 (bs, 4H), 8.05-
8.25 (bs, 2H). FT-IR: ν = [1090, 1120, 1180, 1270, 1300, 1350, 1380, 1450, 1580, 1660, 
1760, 2930, and 2980 cm-1]. Raman: ν = [1440, 1610, 1660, 1730, 2865, 2943, 2983, 
3067 cm-1]. 
 Functionalized poly-lactide derivative 5: Compound 3 (2-(cyclooct-2-yn-l-yloxy) 
acetic acid) has been synthesized according to the literature reported protocol.134 28 mg 
of compound 3 was dissolved in 1 ml of dry dichloromethane under dry argon 
atmosphere. Then 42 mg of DCC and 12.5 mg of DMAP was added to this solution. The 
solution was stirred for 10 min, then 15 mg of polymer 2 was added under argon and 
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  stirred for overnight at RT. All solvents were evaporated to dryness, then the resulting 
polymer 5 was dissolved in minimal amount of dichloromethane, precipitated in cold 
methanol, and dried in vacuum. Functionalization proceeded in good yield at around 90% 
conversion. Polymer 5 characterization: 1H NMR (CDCl3) δ 0.9-1.4 (m, 8H), 1.45-1.95 
(m, 4H), 1.95-2.1 (m, 1H), 2.1-2.2 (m, 2H), 2.2-2.3 (m, 1H), 4.05-4.25 (m, 2H), 4.33 – 
4.42 (m, 1H), 4.5-4.95 (m, 4H), 5.11-5.25 (m, 2H), 5.4-5.6 (m, 1H). FT-IR: ν = [1100, 
1130, 1190, 1200, 1240, 1350, 1380, 1400, 1450, 1770, 2920, and 2980 cm-1]. Raman: ν 
= [1440, 1750, 2200, 2852, 2876, 2943, 2973 cm-1]. 
  
Synthesis of Acrylate and Alkyne Functionalized PLGA (PLGA-acrylate-alkyne): 
 
 PLGA-OH (4.0 g, 0.49 mmol, Mn,theo= 8100 g/mol) was dissolved in 100 mL of 
THF. To this solution was added triethylamine (0.68 mL, 4.90 mol) and the reaction 
mixture was cooled to 0 oC. Acryloyl chloride (0.20 mL, 2.47 mmol) in 20 mL of THF 
was added dropwise over 30 min to this solution under nitrogen. The mixture was stirred 
at 0 oC for 1 h then overnight at room temperature under nitrogen atmosphere. The 
solvent was evaporated and the remaining viscous polymer was dissolved in CHCl3 and 
precipitated into large amount of methanol. The dissolution-precipitation procedure was 
repeated two times. After decantation of methanol, remaining sticky polymer was 
dissolved in CHCl3 and evaporated to dryness to give 3 g polymer as a pale yellow solid. 
The obtained polymer was immediately dissolved in 100 mL of CH2Cl2. To this solution 
were added 4-pentynoic acid (1.09 g, 0.011 mol) and DMAP (0.135 g, 1.11 mmol), 
respectively. After stirring 10 min at room temperature, DCC (2.27 g, 0.011 mol) 
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  dissolved in 20 mL of CH2Cl2 was added to the mixture. Reaction mixture was stirred 
overnight at room temperature under nitrogen. Next, urea by-product was filtered and the 
solvent was removed by rotary evaporation. Remaining viscous polymer was dissolved in 
CHCl3 and precipitated into large amount of methanol. The dissolution-precipitation 
procedure was repeated two times. After decantation of methanol, remaining sticky 
polymer was dissolved in CHCl3 and evaporated to dryness to give the polymer as a light 
brown solid. Yield: 2.5 g (70%). Mn,GPC= 9600 g/mol, Mw/Mn= 1.52 (based on PS 
standarts). 1H NMR (400 MHz, CDCl3, δ): 1H NMR (400 MHz, CDCl3, δ): 6.44 (d, 
CH2=CHC=O), 6.11 (m, CH2=CHC=O), 5.9 (d, CH2=CHC=O), 5.4-5.3 (m, CHCH2O), 
5.2-5.0 (m, C=OCHCH3O), 4.9-4.4 (m, CHCH2OC=O and C=OCH2OC=O), 2.8-2.4 (m, 
CH≡CCH2CH2C=O), 1.96 (s, CH≡CCH2CH2C=O), 1.7-1.5 (m, C=OCHCH3O).  
 
 
Figure 4. 1H NMR spectrum of PLGA-acrylate-alkyne in CDCl3 (400 MHz). 
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 1H NMR spectrum of PLGA- acrylate-alkyne is given in Figure 4, from 1H NMR 
spectrum it is clear that methylene protons adjacent to hydroxyl between δ 4.2-3.8 ppm 
shifted to δ 4.5 ppm and acrylate protons can be seen between δ 6.5-5.8 ppm after 
esterification. In addition, methine proton next to triple bond at δ 1.96 ppm and 
methylene protons next to carbonyl between δ 2.8-2.4 ppm confirmed the structure. 
Besides, the mol percentages of acrylate and alkyne were found to be 16% and 84%, 
respectively from 1H NMR.  
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Appendix B 
Raman Spectroscopy Analysis 
 
 
Appendix B-1: Full Raman spectra of polymer 4 containing compartment. 
 
 
 
Appendix B-1: The full Raman spectra of the compartment containing polymer 4 and PLGA.  Here, 
the 1610 and 1660 nm signals (shown with red arrows) signify the benzophenone functional groups 
present in this polymer. 
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Appendix B-2: Full Raman spectra of polymer 4 and 5 containing compartments 
 
 
 
 
 
 
 
 
 
 
Appendix B-2 4: The full Raman spectra of the compartments containing polymer 4 or 5 in 
tricompartmental microparticles in Figure 2-6.  Here, the top spectra is of the compartment containing 
polymer 5 and PLGA, with the appropriate signals at 2200 cm-1 for cyclooctyne, and the bottom 
spectra is of the compartment containing polymer 4 and PLGA, with the peaks at 1610 and 1660 cm-1 
for benzophenone.  
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Appendix C 
Synthesis and Characterization of Dual Functional Polymers 
 
Characterization 
 1H NMR and 13C NMR spectra were recorded using a Bruker Avance III 500 
spectrometer in CDCl3 and DMSO-d6. Working frequencies were 500 MHz for 1H and 
125 MHz for 13C NMR. Infrared (IR) spectrum of compound 2 was recorded on Bruker 
Alpha spectrometer. The sample was measured as a pure compound using ATR-
technique (ATR = Attenuated Total Reflection). Analysis of the polymer structures was 
undertaken with a Thermo Nicolet 6700 spectrometer with an 85° grazing angle and 128 
scans for each sample at a resolution of 4 cm-1 or with Bruker Vertex 80 spectrometer, 
detector: LN2 cooled narrow band MCT with an 80° grazing angle and 1024 scans for 
each sample at a resolution of 2 cm-1. Reference: deuterated 1-hexadecanethiol self-
assembled monolayer on a gold wafer. Samples were prepared by spin coating of 
polymer solutions (in dry THF or chloroform) on gold wafers. Electron ionization (EI) 
mass spectra were recorded on a Finnigan MAT 95 spectrometer. Gel permeation 
chromatography (GPC) using THF as mobile phase was performed on a Toson EcoSEC 
GPC system with autosampler and a differential refractive index detector at 30 °C and at 
an elution rate of 1.0 mL/min. Three PSS SDV columns (100 Å, 5 µ, 8.0 x 300 mm 1000 
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Å, 5 µ, 8.0 x 300 mm and 100000 Å, 5 µ, 8.0 x 300 mm) were calibrated by linear 
polystyrene standards. GPC using DMAc with 0.03 w/w% LiBr as mobile phase was 
performed on Polymer Laboratories PL-GPC 50 Plus Integrated System with 
autosampler and a differential refractive index detector, at 50 °C with an elution rate of 
1.0 mL/min. A Polymer Laboratories PLgel 5 µm bead-size guard column (7.5 × 50 mm) 
and three Polymer Laboratories PLgel 5 µm MixedC columns (7.5 × 300 mm) were 
calibrated by linear polystyrene standards.  
The particles were visualized using a confocal laser scanning microscopy (CLSM) 
(Olympus, FluoView 500). For this purpose, the particles were deposited on a glass cover 
slip during the jetting process and a drop of water was placed on the cover slip. 405 nm 
laser, 488 nm argon laser, and 533 nm helium-neon green (HeNeG) laser were used to 
excite MEHPV, PTDPV, and TRITC, respectively. The barrier filters were set to 430–
460 nm for MEHPV, 505–525 nm for PTDPV, and >560nm for TRITC. The particles 
were imaged using an Amray 1910 field emission scanning electron microscope (FE-
SEM). To do this, the particles were suspended in water, deposited on silicon wafers and 
left to dry overnight, after which the wafers were sputter coated with gold and imaged. 
The confocal Raman microscopy images were obtained using WITec alpha 300R 
microscope utilizing 532 nm laser. To remove any remaining solvents particles were 
dried in vacuo overnight prior to measurements. Spectra were acquired using an 
integration time of 0.5 sec per pixel with image scan area of 100 pixels x 100 pixels. 
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(4-Nitrophenyl)methyl mercaptoacetate (2)  
Thioglycolic acid (8.3 mL, 0.12 mol, 2 eq) and o-nitrobenzyl alcohol (9.18 g, 0.06 mol, 1 
eq) were dissolved in toluene (90 mL) and concentrated sulfuric acid (0.3 mL) was added 
thereto. The reaction was refluxed for 2 days and solvent was removed in vacuo. The 
crude product was purified chromatographically on silica gel with hexane/ethyl acetate 
(4:1 v/v) mixture as eluent to yield 8.69 g (64%) of the title compound as a yellow liquid, 
which solidified after some time. 1H NMR (500 MHz, CDCl3): δ = 8.09 (dd, J = 8.3 Hz, J 
= 0.9 Hz, 1H, HAr), 7.69–7.60 (m, 2H, HAr), 7.49 (td, J = 8.3 Hz, J = 1.7 Hz, 1H, HAr), 
5.55 (s, 2H, ArCH2O), 3.34 (d, J = 8.4 Hz, 2H, CH2SH), 2.05 (t, J = 8.4 Hz, 1H, CH2SH) 
ppm; 13C NMR (125 MHz, CDCl3): δ = 170.3 (C=O), 147.5 (CAr), 133.9 (CHAr), 131.6 
(CAr), 129.1 (2C, CHAr), 125.2 (CHAr), 63.9 (ArCH2O), 26.4 (CH2SH) ppm; IR (Platinum 
ATR): υ = 3113, 2957, 2854, 2562, 1842, 1724, 1611, 1575, 1517, 1439, 1414, 1375, 
1340, 1309, 1280, 1224, 1142, 1080, 1048, 1023, 979, 965, 936, 860, 795, 730, 671, 600, 
587 cm-1; HRMS (EI) m/z calculated for C9H9NSO4 ([M]+): 227.0252, found 227.0255. 
Poly(allyl glycidyl ether) (1) 
Polymerization was performed in flame dried Schlenk flasks under an argon atmosphere. 
Initiating alkoxide was prepared in situ from 2-methoxyethanol (23.6 µL, 0.3 mmol, 1 eq) 
and potassium naphthalenide in THF solution. Complete formation of 2-
methoxyethanolate was indicated by the maintenance of the solution’s green color. Allyl 
glycidyl ether (3.5 mL, 0.03 mol, 100 eq) was introduced into the reaction vessel with a 
gastight syringe and the reaction was stirred for 72 h at 30°C. Polymerization was 
terminated by the addition of acidified methanol and solvent was removed in vacuo. 
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Monomer conversion was 98% as calculated based on 1H NMR spectrum of crude 
polymer. The crude polymer was purified chromatographically on a silica gel column 
with gradient elution (chloroform to chloroform/methanol 10:0.7 v/v mixture as an 
eluent) yielding 3.35 g (98%) of slightly yellow oil. GPC (THF): Mn 11600 g/mol, Mw 
13100 g/mol, PDI 1.12. 1H NMR (500 MHz, CDCl3): δ = 5.93–5.82 (m, 1H, CH=CH2), 
5.25 (d, 1H, CH=CH2), 5.14 (d, 1H, CH=CH2), 3.98 (d, 2H, OCH2CH=CH2), 3.67–3.43 
(m, 5H, CH2-PEG  + CHPEG + CHPEGCH2O), 3.36 (s, 3H, CH3O) ppm; 13C NMR (125 MHz, 
CDCl3): δ = 135.1 (CH2=CH), 116.9 (CH2=CH), 79.0–78.8 (CHPEG), 72.4 
(OCH2CH=CH2), 70.4–69.9 (2C, CH2-PEG  + CHPEGCH2O), 59.2 (CH3O).  
o-Nitrobenzyl poly(ethylene glycol) (10) 
Purified polymer 1 (0.8 g, 7 mmol of C=C, 1 eq) was dissolved in 3 ml of dry THF under 
an argon atmosphere, 2 (4.9 g, 22 mmol, 3 eq) and AIBN (0.178 g, 1.1 mmol, 0.15 eq) 
were added thereto and the reaction was refluxed for 5 h. Completion of the reaction was 
confirmed by 1H NMR spectrometry by the disappearance of allyl group signal. The 
solvent was removed in vacuo and the residue was purified on a silica gel column with 
gradient elution (chloroform to chloroform/methanol 10:0.7 v/v mixture as an eluent) to 
yield 1.71 g (72%) of the title polymer as a yellow viscous oil. GPC (DMAc): Mn 22100 
g/mol, Mw 27500 g/mol, PDI 1.24. 1H NMR (500 MHz, CDCl3): δ = 8.07 (d, 1H, HAr), 
7.68–7.62 (m, 2H, HAr), 7.52–7.45 (m, 1H, HAr), 5.52 (s, 2H, ArCH2O), 3.70–3.35 (m, 
7H, CH2-PEG  + CHPEG + CHPEGCH2O + OCH2CH2), 3.28 (s, 2H, SCH2C=O), 2.68 (t, 2H, 
SCH2CH2), 1.82 (m, 2H, CH2CH2CH2) ppm; 13C NMR (125 MHz, CDCl3): δ = 169.9 
(C=O), 147.6 (CAr), 134.1 (CHAr), 132.0 (CAr), 129.2 (CHAr), 129.1 (CHAr), 125.2 (CHAr), 
79.2–78.4 (CHPEG), 71.4–70.8 (CH2-PEG), 70.3–70.0 (CHPEGCH2O), 69.7 (OCH2CH2), 
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63.6 (ArCH2O), 33.4 (SCH2C=O), 29.5 (SCH2CH2), 29.1 (CH2CH2CH2) ppm; IR (spin 
coated film on a gold wafer): υ =  2922, 2868, 1741, 1614, 1579, 1530, 1448, 1373, 1346, 
1272, 1132, 1007, 860 cm-1.   
Oxidized o-Nitrobenzyl poly(ethylene glycol) (11) 
Polymer 3 (Mn 22100 g/mol, 150 mg, 0.44 mmol of thioether groups, 1 eq) was dissolved 
in 6 ml of acetic acid and 2 ml of acetonitrile and cooled down to 0 °C. Next, hydrogen 
peroxide solution (30%, 0.4 ml, 3.9 mmol, 9 eq) was added thereto dropwise and the 
reaction was stirred at 0 °C for 6 h. The reaction was slowly poured into 5% sodium 
bicarbonate solution, extracted with dichloromethane, dried over anhydrous sodium 
sulfate, filtered and concentrated in vacuo to yield 147 mg (94%) of the title polymer as a 
yellow viscous oil. GPC (DMAc): Mn 26100 g/mol, Mw 34200 g/mol, PDI 1.31. 1H NMR 
(500 MHz, CDCl3): δ = 8.07 (d, 1H, HAr), 7.71–7.62 (m, 2H, HAr), 7.47 (m, 1H, HAr), 
5.57 (s, 2H, ArCH2O), 3.81 (dd, 2H, SCH2C=O), 3.70–3.40 (m, 7H, CH2-PEG  + CHPEG + 
CHPEGCH2O + OCH2CH2), 2.96 (m, 2H, SCH2CH2), 2.0 (m, 2H, CH2CH2CH2) ppm; 
13C NMR (125 MHz, CDCl3): δ = 165.2 (C=O), 147.4 (CAr), 134.3 (CHAr), 131.2 (CAr), 
129.6 (CHAr), 129.3 (CHAr), 125.2 (CHAr), 79.0–78.5 (CHPEG), 71.1–70.8 (CH2-PEG), 
70.2–69.9 (CHPEGCH2O), 69.7 (OCH2CH2), 64.4 (ArCH2O), 55.8 (O=SCH2C=O), 49.9 
(O=SCH2CH2), 23.2 (CH2CH2CH2) ppm; IR (spin coated film on a gold wafer): υ =  
3243, 2924, 2870, 2375, 1742, 1653, 1613, 1578, 1530, 1447, 1374, 1346, 1276, 1121, 
1057, 860 cm-1. 
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Figure Appendix C-1. Comparative 1H NMR spectra of polymers 1 (A), 10 (B) and 11 
(C). Solvent CDCl3. 
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Figure Appendix C-2. Comparative IR spectra of polymers 10 (blue line) and 11 (red 
line) (A) and their  gel permeation chromatograms (polymer 10 (dashed line), polymer 11 
(solid line)) (B). 
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Appendix D 
Experimental Procedures for Cochlear Analysis 
 
 In vivo infusion: Surgeries were conducted in a sterile environment and utilized aseptic 
technique. For in vivo infusions, Hartley guinea pigs (Charles River Laboratory, 
Wilmington, MA) were anesthetized and a post auricular approach was used to provide 
access to the middle ear. The temporal bone was drilled to visualize the cochlea and a 
fine pick was used to create a small hole in the basal turn of the cochlea near the round 
window. A micro-cannula with a silastic ball was inserted 0.5mm into the basal turn of 
the scala tympani and cyanoacrylate was used to seal the cannula in place as outlined 
previously (Prieskorn & Miller, 2000). The microcannula was made from polyethylene 
10 (PE10) tubing and polyimide (I.D. = 0.12 mm, O.D. =0.16 mm, # 049, MicroLumen, 
Tampa, FL, USA). The silastic ball was made from Sylgard (Dow Corning,Midland, MI). 
A syringe infusion pump (Harvard Apparatus, Holliston, Maine) was used to deliver 
particles into the scala tympani at a flow rate of 1 µl/minute over 5 minutes. Infusions 
were always performed on the left ear and the right ear was used as needed for a 
contralateral control. All animal procedures had been approved by the University 
Committee for the Use and Care of Animals. 
 
Harvesting, cryoprotection, and decalcification of cochlear specimens: Guinea pigs 
were anesthetized and euthanized by injection of sodium pentobarbital (FatalPlus; 
Vortech Pharmaceuticals, Dearborn, MI). In all cases, secondary euthanasia was 
performed by transecting the aorta and the ventricle. Animals were then decapitated and 
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the temporal bones that encase the cochleae were detached. Excess bullar bone was 
removed to facilitate visualization of each  cochlea and then the middle ear bones were 
also detached. Specimens were fixed in 4% paraformaldehyde for 1-2 hours. Following 
fixation, cochleae were decalcified in a solution that was two-thirds formic acid 
(Immunocal; Decal Chemical Corporation,Tallman, NY) and one-third 7% sucrose 
overnight. Prior to freezing, specimens were placed in aluminum containers and 
immersed in a 30% sucrose solution. Freezing was performed by placing the bottom of 
the container in contact with liquid nitrogen cooled 2-methyl-butane (Fisher Scientific, 
Pittsburgh, PA). Specimens were wrapped in parafilm and stored at -80°C until 
sectioning.  
 
Cryostat Sectioning: Samples were cut into 14 µm sections. Slides were generated for 
each animal and samples of the same representative depths from each animal were 
assessed to ascertain particle persistence and distribution. For immunohistochemistry, up 
to 4 midmodiolar sections were taken from the MP infused cochlea of each animal. These 
sections were stained with CD45, a leukocyte antigen, to denote immune cell activity, 
and propidium iodide to indicate the presence of more general cell structures such as 
nuclei. Cryosections of the liver of one of the guinea pigs were also made for use as 
positive and negative (in the absence of primary antibody) controls. 
 
Infused particle number and persistence: A sample of the particle solution was counted 
before the infusions using a hemacytometer.  Persistence and distribution assessments 
were conducted using cryosections from cochleae that had particle infusions 7 days prior 
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to harvest of the cochlea (n=3 for each timepoint). Sections from various depths of the 
cochlea were sampled for particle number. The guinea pig cochlea consists of four turns 
with 2 perilymphatic compartments, the scala tympani and scala vestibule. During 
assessment the location of particles within cochlear cross sections was noted and their 
distribution within the cochlea determined.  
 
Auditory Brainstem Response (ABR): Animals were anesthetized with xylazine (10 
mg/kg intramuscularly) and ketamine (40 mg/kg intramuscularly). Needle electrodes 
(active, reference, and ground) were inserted subcutaneously at the vertex and below each 
pinna and used to record the neurologic response. Up to 1024 responses were averaged 
for each stimulus level, with the stimulus consisting of a 15-msec tone burst, provided at 
10/sec. Pure tones were delivered via a transducer coupled to the external auditory canal 
at 4, 8, and 20 kHz. Initial sound levels were set at 80 dB for pre- and post- infusion tests. 
Threshold determination was based on the visual detection of maximum peak–peak 
amplitude of the resulting waveforms. ABRs were given prior to infusion to enable 
exclusion of animals with abnormal hearing, and to enable detection, if present, of 
threshold shifts post infusion. 
 
Hair cell counts: To prepare specimens for hair cell analysis, ears were harvested in the 
same manner as those used for cryosection preparation with a few notable differences. 
Following removal of the middle ear bones, the apex was visualized under stereoscopic 
magnification and slightly perforated with a 28G needle to create a small hole. Then the 
round window was opened and approximately 300 µL of 4% PFA was infused directly 
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into the cochlea via the hole in the apex. Specimens were postfixed by immersion in 4% 
PFA overnight. The following day, cochleae were rinsed and the otic capsule, lateral wall, 
and tectorial membrane were carefully removed. Phalloidin was used to stain the 
modiolous and the attached organ of Corti. Following rinsing to remove excess stain, the 
organ of Corti was dissected from the modiolous and each turn was mounted onto a 
microscope slide and coverslipped. Phalloidin staining of the organ of Corti enabled 
visualization and counting of both inner and outer hair cells (as indicated by the presence 
of nuclei and/or stereocillia). The counts were performed as described in [Schacht, 2012] 
Counts were then plotted using Cytogram, a custom software, and presented as 
percentage hair cell loss at a particular distance from the apex as compared to a database 
of normal guinea pigs (those not exposed to any external stimuli or agents that could 
induce hearing loss). The tracking of distance along the cochlear spiral also facilitated the 
correlation of areas of loss with known frequency maps of the guinea pig cochlea. This 
provided insight on areas that may be functionally affected by the treatment.  
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